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Abstract 
Sepsis and septic shock are the leading causes of death in intensive care units in North America. 
Approximately 800,000 cases of sepsis are reported every year in the USA and 215,000 will 
succumb to the disease despite aggressive antibiotic and supportive care [1-7]. The incidence of 
sepsis is increasing at a rate of 9% per year even with advances in the understanding of the 
pathophysiology of the disease [1]. Sepsis is commonly induced by bacterial and viral infections. 
Influenza A is the virus that causes the flu. The most recent pandemic caused by Influenza A 
(H1N1) demonstrated the potential of this virus to cause severe complications (viral induced 
sepsis characterized by pneumonia, acute respiratory distress and acute lung injury). This study 
investigated the inflammatory mediators of sepsis in H1N1 infected adults and from adults with 
bacterial induced sepsis. For H1N1 infections lung tissue and sera samples were characterized. 
Lung tissue showed hemorrhage, and interstitial congestion. Cytokine staining of these tissues 
revealed the presence of TNF-α, IFN-γ and IL-1β primarily from the recruited leukocytes. In 
addition TUNEL assay revealed apoptosis occurring in these same cell populations. ELISA 
quantification of sera from H1N1 infected adults also demonstrated high levels of TNF-α, IFN-γ 
and IL-1β at 113 pg/mL, 49 pg/mL and 26 pg/mL respectively. The sera also were able to induce 
apoptosis in cultured fibroblasts that was mediated through STAT1 signalling. The sera from 
bacterial induced sepsis were characterized for the presence of other cytokines and chemokines. 
TNF-α was consistently detected in all septic samples. Chemokine expression was more variable 
across the septic samples. The identification of different mediators of inflammation during sepsis 
will not only increase the basic knowledge about the progression of sepsis but would allow for 
the development of biomarkers that could better predict the progression of sepsis to more severe 
or fatal forms and allow for earlier intervention and treatment of these cases. 
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Chapter1: Introduction 
1.1 Definitions and Epidemiology 
Sepsis is a systemic response to an infection [8]. The definition of sepsis was first clarified in 
1992 by the American College of Chest physicians and the Society of Critical Care medicine 
consensus conference for the definition of sepsis. Before this conference the definitions for 
infection, bacteremia, sepsis, septicemia and septic shock were not precise and used 
interchangeably [8]. An infection is an inflammation caused by a microorganism present in 
normally sterile tissue while bacteremia is a condition where viable bacteria are cultured from 
blood. The term Systemic Inflammatory Response Syndrome (SIRS) is used to describe a non 
infectious inflammatory state sometimes referred to as sterile sepsis. The SIRS criteria include 
the following symptoms: 1) fever with a body temperature either greater then 38˚C or 
hypothermia with a temperature of less then 36˚C, 2) tachycardia with a heart rate of greater then 
90 beats per minute, 3) tachypnea of 20 breaths per minute or greater or a PaCO2 of less then 
32mmHg, 4) leukocytosis with a white blood cell count greater then 12 000 per cubic millimeter 
or leukopenia with a count less then 4 000 per cubic millimeter or less then 10% immature white 
blood cells. Other hemodynamic changes include increased bleeding thrombocytopenia or 
increased coagulation [8, 9]. These clinical symptoms must occur in the absence of other known 
causes to be considered SIRS. Based on these criteria sepsis was defined as SIRS with a 
confirmed infection [8,10]. Sepsis belongs to a continuum of severity of microbial induced 
systemic inflammation. This continuum commences with an infection which progresses to 
sepsis. The progression of sepsis continues to a state of severe sepsis. This state is defined as 
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sepsis with the occurrence of organ dysfunction. The consequences of organ dysfunction include 
hypoperfusion of tissues, vascular hypotension and the metabolic consequences manifesting as 
lactic acidosis, oliguria and alterations in mental status. Alterations in mental status include 
confusion, disorientation, lethargy, agitation and in severe cases coma [9]. Hypotension is 
defined as a systolic blood pressure less than 90 millimeters of mercury or a decrease of more 
then 40%. The most common organ dysfunction occurs in the cardiovascular system and 
respiratory system [11]. Estimates for the incidence of severe sepsis in the I.C.U. was 51 cases 
per 100 000 people per year. When adjusted for age the incidence was estimated to be at a low of 
14 per 100 000 for 20 to 24 years and a high of 58 per 100 000 for 75 to 79 years [11]. 
Progression from severe sepsis leads to septic shock. This is an acute condition characterized by 
persistent hypotension in the presence of fluid resuscitation in addition to the existing conditions 
of severe sepsis. In addition to shock severe sepsis may progress to Multiple Organ Dysfunction 
Syndrome (MODS). This condition is used to describe altered functioning of multiple organ 
systems in critically ill patients. MODS is a term that describes a continuum of organ 
dysfunction. At the most severe end the dysfunction becomes severe enough where the organ can 
no longer maintain homeostasis and failure of interdependent organ systems begins. Progression 
of this condition leads to the most severe states of the sepsis continuum which are multiple organ 
failure and death [8]. These base definitions of sepsis have remained with modifications, 
additions and clarifications from preceding meetings. In 2001 the addition of testing for 
biochemical markers of sepsis was included in the diagnosis of sepsis [10]. These include plasma 
levels of C reactive protein and procalcitonin being greater then 2 standard deviations from 
normal [10]. In 2004 the Surviving Sepsis Campaign created a goal oriented therapy strategy for 
the treatment of sepsis [12]. The first goal is fluid resuscitation to occur as soon as sepsis is 
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recognized. The clinical parameters to achieve by fluid resuscitation are: 1) a central venous 
pressure between 8 and 12 millimeters of mercury, 2) a mean arterial pressure of 65 millimeters 
of mercury or greater 3) urine output of at least 0.5mL per kilogram per hour and 4) central 
venous oxygen saturation of at least 70%. It is recommended that resuscitation occur within the 
first 6 hours of sepsis diagnosis. Regarding the diagnosis of sepsis it is recommended that 2 
cultures be taken before the initiation of antibiotic therapy [12]. The Surviving Sepsis Campaign 
recommends that antibiotic therapy should be initiated with in the first hour of sepsis. Other 
recommendations regarding treatments made by the campaign include source control of the site 
of infection, use of vasopressors when fluid administration fails to adequately increase blood 
pressure, use of inotropic therapy and steroids [12]. Compliance to these recommendations were 
tested in an emergency department and found that greater compliance to the resuscitation module 
gave greater decrease in mortality then low compliance with a 25% reduction in relative risk of 
mortality [13]. 
It has been estimated that globally 31.5 million people will develop sepsis, 19.4 million will 
progress to severe sepsis and 5.3 million people will succumb to sepsis [14]. Sepsis has a large 
financial impact on health care systems. In the U.S. it accounted for 5.2% of the total aggregate 
hospital costs or 20.3 billion dollars and was ranked the most costly condition for 2011 [15]. The 
vast majority of sepsis cases are a result of community acquired infections versus nosocomial 
infections. In the U.S. community acquired sepsis accounted for two thirds of all sepsis cases 
[16] and similarly in Finland 58% of sepsis cases were community acquired [17]. Sepsis 
develops in all age groups but its distribution is bimodal with the greatest mortality occurring in 
the very young and the very old [18]. The mortality due to sepsis drops dramatically after age 
one and remains low until age 55 where there is a large rise to age 75 where mortality peaks at 
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the age group of 85 and older [19]. Males have a higher risk of developing sepsis then females 
[19]. An English study revealed that sepsis accounted for 4.7% of deaths from 2001 to 2010 with 
the annual rates of sepsis in males being 20-28% greater then females [18]. For adults the most 
common sites of infection which led to the development of sepsis are: the lungs, kidneys, urinary 
tract and abdomen [20]. It has been observed that sepsis in older individuals with co-morbidities 
of cancer, chronic kidney disease, deep vein thrombosis, diabetes, dyslipidemia, hypertension 
and obesity contributes an independent increase risk of mortality [20]. Sepsis also leaves lasting 
side effects on those who survive a septic episode. Older survivors of sepsis have a 13% increase 
risk of death one year after sepsis compared to the same age group who never developed sepsis 
and this risk increases with time to a 2 fold increase over non septic individuals 5 years after 
sepsis [20]. In addition to mortality sepsis has a lasting impact on cognitive function. Elderly 
survivors of sepsis when compared to other age matched patient populations from the I.C.U. 
demonstrated greater cognitive impairment. Long term mild cognitive impairment was found in 
the following areas: attention, verbal fluency, verbal memory and executive function [21]. 
The host response to an infecting microorganism is to initiate an inflammatory state designed to 
clear the microbe from the body. If the infection persists and intensifies then the host response 
results in a hyperinflammatory state defined by SIRS. If the infecting organism is not cleared and 
sepsis continues the host response enters an anti-inflammatory state which progresses to a state 
of immunoparalysis. When sepsis is severe and particularly when it occurs in the elderly a long 
lasting immune system dysfunction manifests itself. This is seen in elderly survivors of sepsis 
who tend to have longer hospitalization times, increased number of subsequent infections after 
sepsis that tend to be from opportunistic bacteria, are much more susceptible to developing 
pneumonia and have a greater risk of developing complications from infections when compared 
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to elderly non septic individuals [22].  The elderly and the very young are more susceptible to 
increased mortality and morbidity of sepsis. This may be attributed to the way in which the 
immune system of each group responds during sepsis. In a murine model of sepsis distinct 
differences were found between neonatal mice and elderly mice in the way their immune systems 
reacted to a septic state. Neonatal mice had lower mediators of inflammation in their circulation 
then the control young mice and were less able to recruit immune cells to the site of infection. 
Elderly mice produced much higher levels of inflammatory mediators with greater upregulation 
of reactive oxygen species then controls [23]. 
1.2 Bacteria and Sepsis 
Sepsis can be initiated with a single or localized infection in the host which is termed a nidus of 
infection [24]. Examples of such infections include but are not limited to abscess, pneumonia, 
peritonitis, pyelonephritis and cellulitis. The invading organism which include bacteria, parasites 
or viruses cause a local infection and may circulate in the bloodstream and release components to 
initiate an inflammatory response [25]. Bacteria cause the majority of sepsis cases, whereas 
viruses and parasites are reported in approximately 2-4% of the sepsis cases [1]. Gram-positive 
bacterial induced sepsis is found to be most common with an occurrence of 30-50%. Gram-
negative bacterial induced sepsis, which were predominant in the 1970s and 1980s are less 
frequent with an incidence rate of 25-30% [1]. In addition, polymicrobial infections are 
identified in 25% of sepsis cases. The inflammatory response can be triggered by the presence of 
bacterial toxins, either endotoxins or exotoxins. For example, a component of the Gram-negative 
bacterial outer cell membrane, lipopolysaccharide (LPS) is a classic inducer of the inflammatory 
cascade [4,25,26]. Examples of bacterial exotoxins include Toxic Shock Syndrome Toxin-1 
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(TSST-1) and Toxin A released from Staphylococcus and Pseudomonas species, respectively. 
Further, structural components of the bacteria may initiate a host response including 
peptidoglycan and lipoteichoic acid from Gram-positive bacterial cell wall [1,6,24]. More 
recently,  studies have demonstrated that pure bacterial DNA and RNA can stimulate a host 
response [24].   
1.3 Initiating Molecules of the Inflammatory Response 
The immunological host response to invading organisms includes innate and adaptive immunity 
[7,27,28]. The innate response is the body’s first line of defense and is therefore responsible for 
the recognition of pathogens for subsequent elimination [7,27]. Immune cells including 
neutrophils, monocytes and macrophages are key components of the host response. These cells 
are capable of recognizing structural components or products from bacteria including LPS, 
peptidoglycan and lipoteichoic acid [27,29-33]. These products vary among different strains or 
species; however, all microbes possess an invariable pathogen-associated molecular pattern 
(PAMP) that can be recognized by pattern recognition receptors (PRRs) on innate immune cells 
[31,34,35]. Consequently, PRRs will specifically activate signalling pathways to mediate the 
inflammatory response by releasing pro-inflammatory mediators.  
1.4 Gram-Negative Bacteria 
Previously, the most common infections leading to the development of sepsis were initiated from 
Gram-negative bacteria [1]. The PAMP for this type of bacteria is LPS since it is the principal 
component of the bacterial outer cell membrane [6,30,36,37]. LPS is an amphiphilic 
macromolecule that is composed of three major elements [24,26]. These include the 
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polysaccharide side chain, the phospholipid and the lipid A; the last component being the most 
toxic element of the endotoxin [24]. The lipid A moiety was shown to reproduce many clinical 
and metabolic manifestations observed during septic shock [24]. The presence of LPS in the 
body, even at low levels, activates monocytes and macrophages through recognition of the 
invariant pattern of the lipid A portion [30]. Initially, LPS forms a complex with a plasma protein 
called lipopolysaccharide binding protein (LBP) [24,30,32,37]. The LBP catalyzes the transfer of 
the LPS to a membrane bound receptor termed CD14 on the surface of monocytes and 
macrophages or to a soluble CD14 molecule found in the plasma for activation of CD14 negative 
cells such as endothelial cells [24,32,36]. CD14 along with Toll-like receptors (TLRs) belong to 
the family of PRRs. Subsequent to LPS binding to CD14, LPS is transferred to TLR 4 [24]. TLR 
4 belongs to a family of ten members of which are characteristically identified by the presence of 
leucine-rich repeat (LRR) domain in the extracellular region [27-29]. In addition, TLRs possess a 
cytoplasmic region that is homologous to the interleukin-1 receptor (IL-1R) referred to as the 
Toll/IL-1 receptor (TIR) domain [31]. Consequently, the signalling pathways between the pro-
inflammatory cytokine IL-1 and the TLRs possess similarities. However, the binding of LPS to 
TLR 4 is not sufficient to stimulate an adequate inflammatory response. Shimazu et al have 
shown that an adaptor protein termed MD-2 interacts with TLR 4 on the cell surface which is 
required in order to enhance the inflammatory response. Therefore, LPS recognition by immune 
cells necessitates the formation of large complex whereas TLR 4 will transduce the signal 
downstream to activate transcription factors such as NF-κB and AP-1 that modulate the host 
response [32,38]. TLR 4 is not exclusive to LPS recognition. It is also able to bind to other 
ligands such as Taxol, heat shock proteins (HSP 60 and 70) as well as host extracellular matrix 
components (fibronectin, hyaluronic acid and fibrinogen) [28].  
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1.5 Gram-Positive Bacteria 
Gram-positive bacteria components such as peptidoglycan, a large polymer that provides most of 
the strength and rigidity of bacterial cell walls and teichoic acid, a diverse group of polymers 
found in the cell wall or cell membrane are also able to initiate the inflammatory response. The 
presence of these structural components will be recognized by another member of the TLR 
family, more specifically, TLR 2 [27-29]. Similarly to LPS, peptidoglycan and lipoteichoic acid 
will bind to the TLR receptor in a CD14 dependent manner [33]. However, the accessory protein 
MD-2 is unique to TLR 4 recognition and is not required for the activation of the inflammatory 
response through TLR 2 [28]. Other ligands distinguished by TLR 2 include lipoproteins, 
lipoarabinomannan (mycobacteria), atypical LPS and porins (Neisseria) [28]. In addition, 
researchers have shown that TLR 2 is able to cooperate with other members of the TLR family to 
recognize other microbial components. More specifically, TLR 1 and TLR 6 are functionally 
associated with TLR 2 and are able to discriminate between other ligands such as tri-acyl 
lipopeptides and di-acyl lipopeptides, respectively [28]. Upon ligand recognition by TLR 2, a 
signalling pathway will be initiated to activate transcription factors such as NF-κB and AP-1 that 
modulate the inflammatory response.  
1.6 Bacterial DNA 
Another potent activator of the inflammatory response is bacterial DNA. Bacterial genomic 
DNA contains unmethylated CpG dinucleotides [28,39,40]. In contrast, mammalian DNA has a 
low level of CpG motifs and is usually found to be methylated. As such, innate immune cells are 
able to discriminate between their own DNA and prokaryotic DNA. Thus, CpG motifs are yet 
another example of a PAMP by which TLRs are able to recognize. In this case, TLR 9 has been 
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identified as the family member responsible for the stimulatory effects of the innate response in 
the presence of bacterial genomic DNA [28,29,31,41]. Unlike TLR 1, 2 and 4 which are found to 
be expressed on the cell surface, TLR 9 has been identified as being in the endosome [28,39]. 
Studies have demonstrated that CpG DNA enters the cell by endocytosis and that TLR 9 is 
expressed on the surface of the endosome [28]. Consequently, TLR 9 is able to initiate a 
signalling pathway to activate the AP-1 and NF-κB transcription factors.  
1.7 Double-stranded RNA 
The innate response has also evolved to recognize the presence of viral components such as 
double stranded RNA (dsRNA). dsRNA may be produced during the viral replication cycle [28]. 
It has been demonstrated to be a strong inducer of type I interferons such as interferon alpha 
(IFN-α) and interferon beta (IFN-β) [28]. Furthermore, dsRNA is able to promote the 
transcription of interferon inducible genes and thus stimulate the host response. A synthetic 
dsRNA called polyinosinic-polycytidylic acid [poly (I:C)] has been shown to exhibit similar 
activity to dsRNA [28,41]. The stimulatory effects of dsRNA were thought to originate from a 
protein termed dsRNA-dependent protein kinase (PKR). However, previous studies have 
indicated that other molecules are involved in viral recognition. More specifically, TLR 3 is able 
to respond to the presence of dsRNA and elicit an immunological response through NF-κB 
activation [28,29,31].  
1.8 Bacterial RNA 
Bacterial RNA can also elicit an immunological response. More recently, the notion that TLRs 
can distinguish between mammalian and bacterial RNA through nucleoside modifications was 
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investigated [42]. The majority of cellular RNA is comprised of ribosomal RNA (rRNA) and is 
modified in mammalian cells versus bacterial cells. For example, human rRNA possesses 
approximately ten-fold and twenty-five fold the amount of pseudoouridine and 2’-O-methylated 
nucleosides respectively when compared to bacterial rRNA [42]. Another component of cellular 
RNA is the transfer RNA (tRNA). Humans minimally possess 25% of tRNA modified 
nucleosides whereas bacterial tRNA is rarely modified. Similarly, bacterial messenger RNA 
(mRNA) does not contain nucleoside modifications as compared to human mRNA [42]. Typical 
examples of human mRNA nucleoside modifications include 5-methylcytidine (m5C), N6-
methyladenosine (m6A), inosine, 2’-O-methylated nucleosides and N7-methylguanosine (m7G) 
[42]. Results from in vitro studies indicate that unmodified nucleosides are recognized by 
immune cells through TLR 3, 7 and 8 [42].     
1.9 TLR Receptor Signalling Pathways 
As mentioned previously, a variety of stimuli are able to initiate a host response. These foreign 
antigens are specifically recognized by different members of the TLR family where they 
transduce the signal to downstream effectors. The most common effectors are the transcription 
factors AP-1, NF-κB and IRF [29]. Despite the fact that all the TLR members are able to activate 
NF-κB and MAP kinases with the exception of TLR3, the resulting gene expression profile 
varies among the individual TLR [29]. A possible explanation for this specificity is the adaptor 
proteins being recruited by the TLRs.  
1.9.1 MyD88-dependent Pathway 
The most common intracellular signalling pathway utilized by all TLRs except for TLR3 is the 
activation of NF-κB and MAP kinases through the recruitment of the adaptor protein called 
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MyD88 [27,29]. The signalling pathway will begin in the common TIR domain on the 
cytoplasmic surface of each TLR. A homophilic interaction between the TIR domains of the 
TLR and the C-terminal portion of the adaptor protein MyD88 will occur [27,38]. In turn, the N-
terminus of MyD88 contains a death domain which will recruit a death domain containing 
serine/threonine kinase called IL-1 receptor-associated kinase 4 (IRAK-4) [35,38]. 
Consequently, IRAK-4 becomes activated and phosphorylates IRAK-1. Activated IRAK-1 
recruits TNF receptor associated factor 6 (TRAF6) which ultimately leads to the activation of the 
following kinases:  1) Inhibitor of NF-κB kinase (IKK) complex; 2) p38; and 3) Jun N-terminal 
kinase (JNK) [14,20]. The IKK pathway eventually leads to the activation of the transcription 
factor NF-κB whereas the p38 and JNK mitogen-activated protein kinase signalling pathways 
converge to activate the transcription factor AP-1 [27,38]. 
1.9.2 MyD88-independent Pathway 
In addition, a MyD88-independent pathway has been identified. MyD88 deficient cells are able 
to activate NF-κB and JNK in response to LPS stimulation. However, a delayed reaction is 
observed [28]. In this pathway, a novel adaptor protein termed TIR domain-containing adaptor 
protein (TIRAP)/MyD88-adaptor-like (Mal) was discovered. TIRAP/Mal has a C-terminal TIR 
domain but lacks the N-terminal death domain observed in MyD88 [28-30,35]. Recruitment of 
IRAK-2 by TIRAP/Mal occurs and eventually leads to NF-κB and JNK activation [29,33]. 
Furthermore, stimulation of MyD88 deficient cells by LPS also activates Interferon-Regulatory 
Factor-3 (IRF-3) [28,30]. Consequently, IRF-3 activation induces the expression of many IFN-
inducible genes. 
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1.9.3 Other Adaptor Proteins 
In addition to MyD88, other adaptor proteins have recently been identified that contribute to the 
specificity of TLRs. For instance, TLR4 and TLR3 are both able to recruit a novel protein called 
TIR-related adaptor protein inducing interferon (Trif) [30,41]. Trif  signals through an IKK-like 
kinase called TBK-1 which is required for the phosphorylation and activation of the transcription 
factor IRF3 and IRF7 [35,40]. In addition, another adaptor protein was shown to be involved in 
TLR4 signalling. This protein named Trif-related adaptor molecule (Tram) has been shown to act 
as a bridging adaptor for the subsequent recruitment of Trif [29]. Therefore, this distinct 
individual TLR signalling may explain the various biological responses to different stimuli. 
Furthermore, PAMPs have been shown to activate transcription factors independent of the TLR 
family. For instance, LPS has been shown to activate another family of transcription factors, 
namely, the Signal Transducer and Activator of Transcription (STAT) [28]. STAT-1 deficient 
mice were subjected to LPS and a reduction of IFN-regulated genes was observed. This data 
indicates a potential role of STAT-1 in the response to LPS [28].  
In summary, the recognition of PAMPs by innate immune cells will activate complex signalling 
pathways which ultimately lead to the activation of transcription factors such as NF-κB, AP-1, 
STAT and IRF. Accordingly, these transcription factors will induce the inflammatory response 
through the expression of inflammatory mediators such as cytokines, chemokines, cell-adhesion 
molecules and inducible nitric oxide synthase (iNOS) [34].  
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1.10 Transcription Factors 
1.10.1 NF-κB 
Nuclear Factor-κB (NF-κB) proteins play a significant role in the host response against pathogen 
invasion. Recent studies in animal models of sepsis and septic shock have identified NF-κB as 
having a key role in the pathophysiology of sepsis [42]. NF-κB is a family of structurally related 
proteins that form homodimers and heterodimers with various members of the NF-κB/Rel family 
[42,44]. Such members include NF-κB1 (p50/p105), NF-κB2 (p52/p100), RelA (p65), RelB and 
C-Rel. NF-κB1 (p50) and NF-κB2 (p52) are synthesized as precursor p105 and p100, 
respectively [34, 43-45]. Members of this family can associate to form a variety of dimers which 
have distinct properties and are able to differentially regulate gene expression. The most 
common association is the heterodimer p50/p65 [43]. A common characteristic of this family is 
the presence of a 300 amino acid Rel homology domain. The Rel domain is important for 
dimerization, as well as DNA binding. It is also responsible for binding to a family of inhibitory 
proteins called Inhibitors of NF-κB (IκB). In unstimulated cells, NF-κB subunits are bound to 
IκB proteins. These proteins include IκBα, IκBβ, IκBγ, IκBε, IκBζ, Bcl-3, p105 and p100 
[34,43]. These inhibitory proteins can interact with NF-κB proteins though their characteristic 
ankyrin repeat domain. This interaction masks the nuclear localization sequence on NF-κB 
proteins and thus, serves as a regulatory mechanism by sequestering the transcription factor to 
the cytoplasm [43,44]. The IκB proteins will be phosphorylated by IKKs and thus signalled for 
ubiquitination and degradation upon NF-κB activation by LPS or cytokines [43-46]. Therefore, 
the NF-κB proteins can translocate to the nucleus and bind to its cognate regulatory element to 
modulate gene expression.  
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NF-κB broadly regulates biological functions including the regulation of inflammatory 
mediators. In addition, it has been found to play a pivotal role in the regulation of cell 
proliferation and apoptosis [43,48]. Under normal conditions, NF-κB generates pro-survival 
signals by modulating the anti-apoptotic genes such as inhibitors of apoptosis-1 and -2 (IAP-1 
and IAP-2), the X chromosome-linked inhibitor of apoptosis protein (XIAP) and the cellular Fas-
associated death domain-like IL-1β-converting enzyme (FLICE)-like inhibitory protein (c-FLIP), 
an inhibitor of caspase 8 [43,44]. However, if the activity of NF-κB is deficient or inhibited, the 
cell will undergo apoptosis. In contrast, recent findings have indicated that activation of NF-κB 
can lead to apoptosis through the expression of pro-apoptotic genes such as Fas ligand and c-
Myc. A plausible explanation for this contradiction is the fact that NF-κB may switch from one 
response to another depending on the time and the stimulus [43]. 
NF-κB also plays an important role in adaptive and immune responses. For example, NF-κB is 
required for hematopoiesis and for myeloid and lymphoid cell differentiation in the adaptive 
response [43]. Similarly, during innate immunity, NF-κB plays a pivotal role in the development 
and maturation of hematopoietic cells such as macrophages and neutrophils [43]. More 
importantly is NF-κB’s role in the inflammatory response. NF-κB modulates the expression of 
many pro-inflammaotory mediators such as cytokines, chemokines, cell-adhesion molecules and 
iNOS [34,44]. An increased transcriptional level of pro-inflammatory mediators is thought to be 
the hallmark of the pathophysiology of sepsis [43]. Previous studies have implicated NF-κB in 
the pathogenesis of septic shock. Approximately 200 genes that have been implicated in the 
pathophysiology of sepsis and septic shock  contain NF-κB regulatory elements in their 
promoters [43]. NF-κB regulated genes include:  cytokines (TNF-α, IL-1β); chemokines 
(macrophage inflammatory protein (MIP)-1α, regulated on activation normal T cell expressed 
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and secreted (RANTES); adhesion molecules (ICAM-1, VCAM-1, E-selectin); and enzymes 
(iNOS, phospholipase A2). Interestingly, the activity of NF-κB seems to correlate with the 
severity of the disease [34,43].  
1.10.2 AP-1 
The Activator Protein 1 (AP-1) is a complex of DNA binding proteins that belong to the basic 
region-leucine zipper (bZIP) family [47-49]. The basic leucine zipper is required for DNA 
binding as well as for interaction with other family members to form dimers. The formation of 
dimers is essential for recognition and binding to the palindrome DNA promoter sequence 
[47,49]. The AP-1 complexes can form homodimers with Jun family members (c-Jun, v-Jun, 
Jun-B and Jun-D) or heterodimers with Fos family members (c-Fos, Fos-B, Fra-1, or Fra-2) [47-
49]. The properties of the basic leucine zipper of Fos family members does not allow 
homodimerization [47]. In addition, Jun and Fos can form heterodimers with other bZIP family 
members such as Activating Transcription Factor (ATF) and Maf [48]. Therefore, the subunit 
composition of the AP-1 complexes can vary significantly which leads to differential gene 
expression [49].  
The heterodimer c-Jun/c-Fos is expressed in the majority of cell types [48]. However, a variety 
of stimuli can promote dimerization. These stimuli include cytokines (TNF-α, IL-1, IFN-γ), 
growth factors, serum, oncoproteins and cellular stress [48,49]. The induction of AP-1 activity 
upon these stimuli indicates that AP-1 is involved in growth regulation as well as inflammatory 
and innate immune responses [49]. Several stimuli dependent mechanisms exist that lead to AP-1 
activation. For example, growth factors will induce AP-1 activity through a subfamily of the 
mitogen-activated protein kinases (MAPKs) called the extracellular signal-regulated kinases 
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(ERK) [47,49]. Upon pro-inflammatory cytokine stimulation, the activation of AP-1 will most 
likely utilize two other MAPKs subfamilies called JNK and p38 [49]. The p38 MAPKs are 
involved in fos and c-jun gene induction [49]. Subsequently, JNK will bind and phosphorylate c-
Jun thereby increasing the transcriptional activity. The Fos/Jun heterodimers subsequently bind 
to AP-1 promoter sites and regulate the gene expression. AP-1 regulates the expression of 
numerous cytokines and  tissue-destructive enzymes such as collagenase [48]. Similar to NF-κB, 
AP-1 has also been shown to induce the expression of apoptotic and survival related genes. For 
example, AP-1 has previously been shown to induce the expression of the proapoptotic gene Fas-
ligand (FasL) [49]. Cyclin D is another important gene regulated by AP-1 and may play a role in 
proliferation and cell death [49]. Cyclin D primarily induces cell proliferation, however, when 
overexpressed, cyclin D contributes to apoptosis in certain cell types [49]. An additional target 
gene for induction of apoptosis by AP-1 is p53. High levels of c-Jun repress p53-mediated p21 
induction thereby allowing p53 activity to promote apoptosis [49]. In summary, AP-1 is a 
transcription factor that is activated in response to growth factors and cytokines that mediates 
gene expression involved in inflammatory and immune response as well as cell survival and 
apoptosis.  
1.10.3 STAT 
The Signal Transducers and Activators of Transcription (STAT) are cytoplasmic proteins that 
belong to a family of seven members [50,51]. The STAT members are STAT 1, STAT 2, STAT 
3, STAT 4, STAT 5a, STAT 5b and STAT 6 [37-39]. A wide variety of extracellular signalling 
polypeptides can activate STAT transcription factors. Examples of STAT activators are the 
epidermal growth factor (EGF), platelet-derived growth factor (PDGF), colony-stimulating 
factor-1 (CSF-1), the pro-inflammatory cytokines interferon alpha (IFN-α), interferon beta (IFN-
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β), interferon gamma (IFN-γ) and interleukins (IL) 2 to 7, 10 to 13, and 15 [50,52,53]. During 
cytokine signalling, the extracellular ligand binds to its cognate cell surface receptor and activate 
the Janus protein tyrosine kinases (JAKs) [54,55]. The JAKs autophosphorylate and 
phosphorylate tyrosine residues on the cytoplasmic domain of the surface receptor [52]. 
Consequently, the STAT proteins are recruited to the receptor through their src-homology 2 
(SH2) domains which recognize and bind to phosphorylated tyrosines [50,51]. The bound STAT 
proteins will in turn be tyrosine phosphorylated by JAKs. Once phosphorylated, the STAT 
proteins will form homodimers or heterodimers depending on the ligand and dissociate from the 
receptor. Once dissociated, the dimer translocates to the nucleus and regulate gene expression 
[50,52,55,56]. Conversely, non-cytokine activators such as EGF, PDGF and CSF-1 are able to 
activate the STATs directly through their receptor tyrosine kinases, and therefore, do not require 
the JAK activation.  
Differential gene expression will occur due to the various dimer combinations. The majority of 
the STAT proteins form homodimers, however, heterodimers such as STAT 1-STAT 2 as well as 
STAT 1-STAT 3 are able to form in response to cytokines [50,52]. Subsequently, the dimers 
translocate to the nucleus and bind to specific promoter sequences and mediate gene expression 
of target genes. The dimerized STATs bind to a specific sequence called the gamma-activating 
sequence (GAS) [52]. The GAS is present in IFN-γ inducible genes including transcription 
factors (IRF-1, IRF-8), adhesion molecules (ICAM) and chemokines (IFN-γ-induced monokine 
[MIG]) [42].  
However, if STAT1-STAT2 heterodimer form a complex with a DNA binding adaptor protein 
called p48, also known as IRF9 and ISGF3γ, the complex will preferentially bind to an interferon 
alpha-stimulated gene response element (ISRE) [52]. The ISRE is present in a variety of genes 
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including; transcription factors (IRF-1, IRF-2); cytokines (IL-6, IL-2); enzymes (2’-5’ 
oligoadenylate synthetase, iNOS, PKR), chemokines (chemokine ligand 5 [CCL5]) and adhesion 
molecules (ICAM-1, VCAM-1) [57]. In summary, the Stat family members broadly regulate cell 
cycle, cell adhesion, apoptotic and iNOS genes which are found to be implicated in the 
pathogenesis of sepsis.  
1.10.4 IRF 
Interferon Regulatory Factor (IRF) is a family of transcription factors comprised of nine 
members; IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 and IRF-9/p48/ISGF3γ 
[54,58]. All members contain a characteristic DNA binding motif in the N-terminal region to 
which they bind to ISRE, interferon consensus sequence (ICS) or interferon regulatory factor 
element (IRF-E) also known as positive regulatory domain (PRD) I and III [59-62]. In general, 
the expression of IRF members is constitutive and is activated by post translational modifications 
such as phosphorylation or acetylation. Certain IRF members can be induced in response to 
cytokines such as IFNs, TNF, IL-1, IL-6, dsRNA and viral infection [54]. The IRF family 
members differentially regulate the transcription of many genes including: cytokines (IFN-α, 
IFN-β, IL-18), chemokines (RANTES, IP-10) and enzymes (PKR, iNOS, 2’-5’OAS) [42,44]. 
These genes are directly involved in the innate immune response against viral infections [54]. 
Furthermore, IRFs are involved in regulating processes such as cell growth inhibition, 
hematopoietic differentiation, cytokine signalling and apoptosis [58,59].   
In summary, transcription factors such as NF-κB, AP-1, STAT and IRF are activated in response 
to pathogen invasion. Consequently, these proteins will modulate the expression of hundreds of 
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genes involved in biological processes such as inflammatory and innate response, cell cycle and 
apoptosis. 
1.11 Inflammatory Mediators 
The inflammatory response is designed to eradicate the microorganism and allow for potential 
tissue repair. However, an excessive pro-inflammatory response may lead to tissue injury and 
organ dysfunction [7]. Therefore, the host response should be tightly regulated in order to 
maintain a balance between a protective inflammatory response and one that is detrimental to the 
individual. During sepsis, this balance is shifted towards an overwhelming pro-inflammatory 
response and thus leads to cellular dysfunction, tissue damage, organ dysfunction and 
potentially, death [7]. This next section will describe important pro-inflammatory mediators 
which have been shown to play a role in the pathogenesis of sepsis. Cytokines are important 
mediators of the inflammatory response and also serve to amplify the host response. Of these, 
tumor-necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and interferon gamma (IFN-γ) 
have been shown to be elevated in serum from septic patients [63,64].   
1.11.1 Tumor Necrosis Factor-alpha 
Tumor necrosis factor-alpha (TNF-α) is a potent cytokine synthesized by a variety of cell types 
which include macrophages, monocytes and lymphocytes in response to inflammation or injury 
[64-66]. TNF-α plays a pivotal role in the immune response by modulating the expression of 
other cytokines, chemokines and cell-adhesion molecules in order to promote the extravasation 
and attraction of leukocytes to the site of infection [66]. However, systemic and chronic 
production of TNF-α which occurs during sepsis, can have harmful effects on various tissues and 
organs possibly resulting in death [65]. For example, TNF-α induces fever (via IL-1β) and 
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stimulates the acute-phase response (via IL-6) [64,65]. Further, TNF-α activates the coagulation 
cascade and induces myocardial depression as well as vascular leakage when present at high 
concentrations [65]. This finding was confirmed through the administration of TNF-α to animals 
in a variety of sepsis experiments. The physiological response of the animals to TNF-α closely 
mimicked the clinical manifestations observed during septic shock including cardiovascular 
collapse, hypotension, intravascular coagulopathy and myocardial suppression [65]. Elevated 
levels of circulating TNF-α have been reported in patients with sepsis and septic shock [64]. In 
addition, a correlation was established between  elevated levels of TNF-α and the severity or 
poor outcome of septic patients [64].  
TNF-α exerts its cellular effects when the soluble trimer binds to its cell-surface receptor [64]. 
There are two distinct cell surface receptors that have been identified for TNF-α: type I or 
TNFR1 and type II or TNFR2 which preferentially bind to soluble and membrane bound TNF-α, 
respectively [64,66-69]. The majority of cell types constitutively express TNFR1 whereas 
TNFR2 is tightly regulated. The majority of the biological actions of TNF-α will be initiated 
through TNFR1 [64,65,67,68]. Binding of TNF-α to its receptors will ultimately lead to the 
activation of the transcription factors AP-1 and NF-κB. TNF-α can also initiate a caspase 
signalling cascade leading to apoptosis [66,67]. Recent findings of the formation of two distinct 
signalling complexes have provided a plausible explanation in the selection of either the pro-
survival or apoptosis processes [70].  
The TNF-α homotrimer will bind to TNFR1 which will initiate receptor trimerization. This 
conformational change will result in the recruitment of the adaptor protein called TNFR1-
associated death domain protein (TRADD) through TNFR1’s cytoplasmic death domain (DD) 
[70]. Once TRADD is recruited to TNFR1, it will serve as a platform to recruit subsequent 
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proteins. These secondary proteins are receptor-interacting protein 1 (RIP1), TNF-receptor-
associated factor 2 (TRAF2) and a member of the Inhibitors of Apoptosis family called cIAP1 
[70]. Hence, TNFR1, TRADD, RIP1, TRAF2 and cIAP1 will form a complex termed Complex I 
which is formed early after receptor activation. Consequently, RIP1 will recruit a macromolecule 
called the “signalosome” [70]. The signalosome is composed of three major proteins; inhibitor of 
NF-κB kinase 1 (IKK1), inhibitor of NF-κB kinase 2 (IKK2) and inhibitor of NF-κB kinase γ 
(IKKγ) also called NEMO [71]. These kinases are able to phosphorylate the inhibitors proteins 
of NF-κB (IκB). NF-κB is tightly regulated by residing in the cytoplasm when associated with 
IκB. Once phosphorylated, IκB will be ubiquitinated and degraded by the proteosome [71]. Once 
IκB is degraded, the liberated NF-κB monomers dimerize and translocate to the nucleus where 
they bind to their cognate regulatory elements and modulate the expression of target genes. 
In contrast, a few hours after TNFR1 activation or possibly after receptor internalization, the 
TRADD-based complex can dissociate from the receptor [70]. Once dissociated, this allows for 
the formation of Complex II through the recruitment of Fas-associated death domain protein 
(FADD) and Caspase 8 [70]. This complex will promote cell death which will be discussed in 
further details in the following sections. 
In summary, TNF-α is a primary mediator of the immune response through the activation of 
transcription factors such as NF-κB and AP-1. Hence, TNF-α is able to amplify the host response 
by modulating the expression of inflammatory mediators. 
22 
 
1.11.2 Interleukin-1 Beta 
Interleukin-1β (IL-1β) is a pro-inflammatory cytokine that is produced mainly by mononuclear 
phagocytes and neutrophils when triggered by bacterial products such as LPS or by cytokines 
such as TNF-α [7,64]. IL-1β is synthesized as a 31 kDa precursor and is proteolytically cleaved 
by interleukin-1 converting enzyme (ICE), also known as caspase 1, into an active 17 kDa 
fragment [72]. IL-1β plays a pivotal role in the regulation of innate immunity by stimulating the 
expression of genes such as chemokines, cytokines and cell surface receptors. Similar to TNF-α, 
the biological effects of IL-1β are dependent on its concentration. At low levels, IL-1β will 
primarily act on endothelial cells to increase surface molecules for leukocyte recruitment as well 
as promote a coagulation response [7]. In high quantities, IL-1β will exert systemic effects such 
as fever, acute phase plasma protein production, leukocytosis and thrombocytosis [73]. Previous 
studies have indicated that IL-1β may play a role in the pathogenesis of sepsis [63]. For example, 
deletion of the IL-1 receptor in mice resulted in increased resistance to endotoxin lethality. 
Furthermore, increased levels of IL-1β have been documented in spontaneous human sepsis and 
septic shock [48]. Elevated levels of IL-1β have been correlated with increased mortality. TNF-
α, and IL-1β are found to be the primary mediators of septic shock [64,73].   
IL-1β binds to two membrane receptors, the IL-1 receptor 1 (IL-1RI) and the IL-1 receptor 2 (IL-
1RII). However, only IL-1RI transduces the signal to downstream effectors whereas IL-1RII acts 
as a decoy [74]. Upon IL-1β binding to IL-1RI, IL-1RI will recruit an accessory protein called 
IL-1RAP through heterodimerization of their common cytoplasmic TIR domains [72]. 
Consequently, signalling will occur through the recruitment of MyD88, IRAK1, IRAK4 and 
TRAF6 adaptor proteins as previously described for TLR MyD88 dependent signalling pathway 
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[72]. Therefore, IL-1β will induce the activation of NF-κB and MAPK pathways and amplify the 
host inflammatory response.  
1.11.4 Interferon Gamma 
Interferon-γ (IFN-γ), also known as type II interferon, is a pro-inflammatory mediator produced 
by activated natural killer (NK) cells and T-helper cells [54,63]. Cytokines such as TNF-α, IL-2 
and IL-12 will enhance the transcription of IFN-γ [57,75]. IFN-γ is involved in biological 
processes which include antiviral and immune responses, cell growth and differentiation and 
apoptosis [54,57]. The main role of this pro-inflammatory cytokine is to activate mononuclear 
phagocytes [75]. IFN-γ initiates signalling pathways that culminate in the synthesis of enzymes 
implicated in the respiratory burst and thus allows for macrophages to phagocytose the invading 
microbe [75]. In addition, IFN-γ activates neutrophils which lead to an up-regulation of the 
respiratory burst. Also, vascular endothelial cells are activated by IFN-γ thereby stimulating 
lymphocyte adhesion and extravasation. Further, IFN-γ increases the expression of Class II 
Major Histocompatibility Complex (MHC) on the surface of a wide variety of cell types [54,75]. 
As a result, there is enhanced antigen presentation on T cells which amplifies the recognition 
phase of the immune response. IFN-γ has also been implicated in the pathogenesis of septic 
shock. In vitro administration of LPS, TNF-α, IL-1β and IFN-γ has been shown to have 
synergistic effects mimicking the adverse hemodynamic effects observed during septic shock 
[63].   
IFN-γ binds to its cognate cell surface receptor which is composed of two subunits; the IFN-γ 
ligand-binding IFNGR-1 subunit and the accessory IFNGR-2 subunit [54]. Upon ligand binding, 
heterodimerization of the receptor subunits will occur and allow for subsequent signal 
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transduction through the JAK-STAT pathway. IFNGR-1 subunit will interact with JAK-1 
whereas IFNGR-2 interacts with JAK-2 [54]. These kinases will recruit latent cytoplasmic STAT 
1 and allow for homodimerization. Subsequently, the dimer will translocate to the nucleus and 
bind to the GAS sequence and regulate the expression of target genes [54]. Therefore, IFN-γ 
amplifies the inflammatory response through STAT activation and expression of IFN-induced 
proteins.  
1.11.5 Other Important Cytokines and Mediators 
Transforming growth factor-beta (TGF-β) is an important cytokine which has been recently 
implicated in the pathogenesis of septic shock. TGF-β is expressed in nearly all cell types and 
plays a pivotal role in the normal development of embryonic tissues including the heart. In 
adults, TGF-β has been implicated in tissue repair and fibrosis. During sepsis, TGF-β counteracts 
the actions of TNF-α and IL-1β in the acute phase of the inflammatory response [64]. The 
synergistic combination of TNF-α and IL-1β has been shown to partially mediate myocardial 
depression that occurs during septic shock [76]. A recent study demonstrated a dose dependent 
reversal of TNF-α and/or IL-1β induced myocardial contraction depression by TGF-β [77]. 
Interleukin 6 (Il-6) is a cytokine that is described as having both pro- and anti-inflammatory 
effects [78]. IL-6 is synthesized by activated monocytes, macrophages, vascular endothelial 
cells, fibroblasts and activated B and T lymphocytes [63-65]. IL-6 levels are influenced by other 
cytokines, including TNF-α and IL-1 in humans [78]. The biological actions of IL-6 ar 
manifested in hepatocytes, B cells and other cell types. IL-6 induces the production of acute-
phase hepatic proteins [63-65] and as a result, there is an augmentation in circulating fibrinogen 
and other proteins that are involved in the transportation and coagulation system. In addition, IL-
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6  functions as a growth and differentiation factor for activated B cells [65]. IL-6 does not seem 
to be directly involved in stimulating tissue injury, however, IL-6 plasma levels are steadily 
elevated in patients with sepsis [63,65,78]. Also, a correlation has been established between the 
elevated levels of IL-6 and poor outcome in sepsis patients [78] and this implies that IL-6 may be 
an important marker of systemic inflammation [65]. 
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine which is 
ubiquitously produced in organs including the heart [79]. Upon exposure to a variety of stimuli 
including endotoxin, toxic shock syndrome toxin 1 and cytokines (TNF-α and IFN-γ), MIF is 
produced by monocytes and macrophages [63]. MIF will amplify the host response by increasing 
the production of other pro-inflammatory mediators. Elevated levels of MIF have been 
documented in patients in septic shock [64] and previous studies have identified MIF as a 
myocardial depressant factor implicated in LPS induced cardiac dysfunction [79].  
High mobility group box 1 protein (HMGB1) has also been implicated in the pathogenesis of 
sepsis and more specifically, Gram-negative sepsis. HMGB1 was initially identified as a nuclear 
DNA binding protein and transcription factor [80] and has  been recently characterized as a 
cytokine that binds to cell surface receptors including TLR2 and TLR4. HMGB1 plays a role in 
the following processes: fever, epithelial barrier dysfunction, chemotactic cell movements, 
release of pro-inflammatory cytokines and acute inflammation [80,81]. HMGB1 is expressed by 
macrophages after exposure to early pro-inflammatory cytokines which include TNF-α and IL-1 
[64]. Administration of LPS to mice resulted in high levels of HMGB1 in the serum 8-32 h post 
exposure. Also, elevated levels of HMGB1 were noted in patients succumbing to septic shock 
[64,82]. 
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In summary, cytokines are rapidly produced in response to invading pathogens by mononuclear 
phagocytes and other cell types. These cytokines will bind to their cognate cell surface receptors 
and stimulate the transcription of genes involved in the host response.  
1.11.6 Inducible Nitric Oxide Synthase 
Nitric oxide (NO) is a cellular mediator that is produced in the endothelium and other cell types 
[83]. NO is a potent vasodilator that mediates the acute inflammatory response by increasing the 
blood flow and therefore, optimizes the delivery of soluble mediators and inflammatory cells to 
the site of infection [83]. NO is produced by the enzyme called NO synthase (NOS) [83] and the 
three NOS isoforms are endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS 
(iNOS). eNOS and nNOS are constitutively expressed whereas iNOS is induced in response to a 
variety of stimuli which include microbial products and cytokines (TNF-α, IL-1, IFN-γ) [65,83]. 
Monocytes/macrophages, neutrophils, endothelial cells and smooth muscle cells are all capable 
of producing NO by iNOS. NOS utilizes the essential amino acid L-arginine as its substrate to 
yield NO and L-citrulline [84]. In the absence of the substrate, NOS generates a product called 
superoxide. The production of NO, in combination with the vasodilator substance prostaglandins, 
will subsequently cause smooth muscle relaxation through a guanosine 3’, 5’-cyclic 
monophosphate (cGMP) mechanism [65,83]. Therefore, NO that is generated in the endothelium 
plays an important role in regulating the vascular tone, blood pressure and blood flow 
distribution [84,85]. Other major roles of NO are its ability to inhibit leukocyte aggregation as 
well as reduce platelet aggregation.  
During sepsis, LPS and pro-inflammatory cytokines such as TNF-α, IL-1β, and IFN-γ contribute 
to the induction of iNOS [65,83], consequently, excessive amounts of NO are produced. The role 
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that iNOS plays in the pathogenesis of septic shock has been the subject of controversy for many 
years. Evidence supporting this hypothesis is found in animal models of sepsis and septic shock 
which have shown increased plasma levels of NO byproducts such as nitrate and nitrite [83]. 
Administration of inhibitors to NO synthesis prevented LPS induced hypotension and showed 
decreased plasma levels of nitrate and nitrite [83]. Interestingly, administration of iNOS 
inhibitors several hours post-endotoxin introduction were shown to reverse the effects of septic 
shock which include hypotension and vascular leaks [83]. Other evidence supporting NO’s role 
in the pathogenesis of sepsis include studies using iNOS knock-out mice. LPS and cecal ligation 
puncture (CLP) models of septic shock both demonstrated increased survival and clinical 
improvements in the iNOS knockouts when compared to wild type mice [83]. In contrast, several 
experimental studies have demonstrated that administration of inhibitors of NO synthesis had no 
beneficial effects. It has also been shown that in human models of sepsis and septic shock, 
measurements of plasma levels of nitrite and nitrate in patients revealed elevated levels. 
Treatments with certain inhibitors of NO synthesis in clinical trials have demonstrated short term 
hemodynamic effects which include improvements in the mean arterial pressure and systemic 
vascular resistance. However, a decrease in the cardiac output was also noted  [83]. Recent 
clinical trials had to be terminated due to increased mortality in the treatment group. In summary, 
NO may contribute to the cardiovascular alterations observed during sepsis and septic shock 
including vasodilation, hyporeactivity to vasopressors and myocardial dysfunction. NO rapidly 
reacts with other free radicals, for example superoxide radical (O2
-
), to generate highly reactive 
oxidant species including peroxynitrite that lead to tissue damage. However, blocking NO 
synthesis as a therapeutic intervention for sepsis is still a matter of debate.  
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1.11.7 Cell-adhesion Molecules and Chemokines 
The acute inflammatory response to infection requires the recruitment of leukocytes to the site of 
inflammation in order to eradicate the pathogen. Bacterial products and cytokines will induce the 
expression of adhesion molecules on the surface of endothelial cells and leukocytes to mediate 
this interaction [75,86]. Adhesion molecules play vital roles in processes which include cell 
growth and differentiation. However, during an inflammatory response, adhesion molecules are 
responsible for immune cell transmigration and response [75,86]. Endothelial cells and 
leukocytes possess complementary surface adhesion molecules which allows the leukocyte to 
roll along the endothelium following a gradient of chemokines and the leukocyte can eliminate 
the pathogen by phagocytosis [65,86]. Initially, leukocytes will migrate to the endothelium, also 
called tethering/rolling, through selectin mediated interactions. Selectins are a family of surface 
adhesion molecules comprised of three members. These include E-selectin, P-selectin and L-
selectin [65,86]. P-selectin is constitutively expressed and stored in endothelial cells and 
platelets. Upon stimulation by leukotrienes, oxidants and complement, P-selectin will be 
expressed on the surface of endothelial cells. E-selectin is expressed by endothelial cells in 
response to LPS and cytokines such as IL-1. L-selectin is expressed on leukocytes and, upon 
endothelial cell activation, undergoes a conformational change. Once released, L-selectin will 
accumulate in the plasma as a soluble protein [87]. E-selectin will mediate the initial interaction 
with activated leukocytes. The leukocytes will tether and roll along the endothelium and 
subsequently become firmly adhered to the endothelium through integrin binding. Integrins are 
expressed on the surface of leukocytes and will interact with ligands such as intercellular 
adhesion molecules (ICAMs) on the surface of endothelial cells [65]. This firm adherence will 
allow for subsequent diapedesis and chemotaxis [75]. 
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Once the leukocytes are firmly attached to the endothelium, they will penetrate the endothelium 
and migrate to the extravascular inflammatory area. This process is also mediated by adhesion 
molecules which include the platelet-endothelial cell adhesion molecule-1 (PECAM-1) [65,75]. 
Therefore, the tethering/rolling, adherence and diapedesis are mediated by interaction of 
adhesion molecules on leukocytes and endothelial cells which ultimately leads to the infiltration 
of leukocytes to the site of infection [65,75].  
Adhesion molecules are an integral part of the host response through the recruitment of 
leukocytes to the site of infection for subsequent elimination of the pathogen. However, 
excessive expression and activation of these molecules will lead to tissue injury as seen during 
sepsis and septic shock [88]. During sepsis, E-selectins, P-selectin, ICAM-1, ICAM-2 and 
VCAM-1 are overexpressed and cause the recruitment of leukocytes at non-infectious locations 
[88]. Consequently, there is destruction of the endothelial barrier which results in loss of fluid 
from the circulation into the surrounding tissue. Therefore, during sepsis, the overexpression of 
adhesion molecules induces the destruction of healthy tissue.  
Chemoattractants such as complement components and chemokines also play a pivotal role in 
the elimination of the invading pathogen [65]. These soluble molecules are necessary for the 
migration of leukocytes to the site of infection [89]. In addition, chemokines have been shown to 
be involved in other biological processes including cellular differentiation and activation, 
angiogenesis/angiostasis, lymphocyte recirculation and immune surveillance [89]. Four families 
of chemokines have been identified thus far based on the cysteine residues in the N-terminus 
[65]. These include: CCL1 through CCL28; CXCL1 through CXCL16; XCL1 through XCL2; 
and CX3CL1 [89]. Chemokines are further classified as being either constitutive or inducibly 
expressed. Inducible chemokines play a role in the recruitment of cells to the site of injury [89]. 
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For example,   IL-8 (CXCL8), RANTES (CCL5), MIP-1β (CCL4), MCP-1 (CCL2) and IP-10 
(CXCL10) are induced in response to stimuli such as LPS, IL-1 and TNF-α [89].  
Chemokines have been shown to play a key role during sepsis through immuno-modulating 
mechanisms. A correlation between chemokines and tissue pathology, organ dysfunction and 
failure has been documented [89]. Elevated levels of IL-8 (CXCL8) have been measured in the 
blood of septic patients [89]. IL-8 plays a role in the recruitment of neutrophils. Increased levels 
of MCP-1 (CCL2) have correlated with the disease course of sepsis. Experimental data have 
revealed increased expression of MIP-1α (CCL3) and RANTES (CCL5) upon LPS stimulation 
[89]. Similarly, increased levels of MIP-1α (CCL3) and RANTES (CCL5) have been 
documented in human septic patients [89]. Therefore, chemokines are also implicated in the 
pathogenesis of septic shock.   
1.11.8 Complement System 
The complement system is also an integral part of the innate immune response. Its main role is to 
promote inflammation and eliminate the pathogen. The complement system is mostly involved in 
controlling bacterial infections, preferentially Gram-negative infections [80]. Microbes have 
been shown to activate the complement system during tissue injury and cellular injury associated 
with burns or traumas. There are three major complement pathways that ultimately lead to the 
destruction of the invading organism. These include: the classical pathway activated by surface 
bound IgM or IgG antibodies; the alternative pathway stimulated by microbial surface 
molecules; and the lectin pathway activated in response to mannose-binding lectin [80]. 
Consequently, these pathways, through a series of enzymatic cascades, will generate C3a and 
C3b, cleavage products from the complement component C3 [65,91]. C3a is a neutrophil 
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chemoattractant whereas C3b will promote phagocytosis by binding to the surface of microbes. 
C3b is able to initiate the cleavage of the complement component termed C5 by associating with 
other components to form a proteolytic complex [65]. The cleavage products of C5 are C5a and 
C5b [50]. Similar to C3a, C5a is a chemoattractant for neutrophils and also alters the vascular 
permeability at the site of infection [91]. The cleaved C5b proteins will form pores on membrane 
structures by associating with other factors such as C6, C7, C8 and C9 which ultimately lead to 
cell lysis.  
Therefore, an inflammatory response will activate the complement system and produce 
inflammatory mediators such as C5a and C3a which can activate neutrophils and thus amplify 
the host response. During sepsis, the complement system is overactive and there is excessive 
production of C5a [91,92]. Recent evidence has shown that the amount of C5a in the serum 
correlates to the severity of the disease [92]. The generation of C5a compromises neutrophil 
function during sepsis.  
1.11.9 Coagulation 
Recently, the interaction of the coagulation pathway with the inflammatory cascade has been 
implicated in the pathogenesis of sepsis and MODS [93]. The coagulation pathway is activated 
in response to tissue injury or infection. There are two pathways in the coagulation cascade 
consisting of the intrinsic pathway and the extrinsic pathway [65]. The intrinsic pathway is 
generally activated in response to tissue injury whereas the extrinsic pathway is triggered by the 
production of tissue factor (TF) [65]. These pathways will converge and lead to the increased 
production of thrombin. Consequently, thrombin will cleave fibrinogen into fibrin forming a 
blood clot [65].  
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During sepsis, the extrinsic pathway is the primary mediator of the coagulation response to the 
infection [65]. TF is produced by endothelial cells and monocytes in response to cytokines 
(TNF-α, IL-1 and IL-6) and C-reactive protein [7,65,94]. In turn, this triggers the extrinsic 
coagulation pathway which ultimately leads to the formation of thrombin. In addition, the 
coagulation cascade will contribute to a pro-inflammatory response. For example, production of 
thrombin and tissue factor-VIIa can induce the production of pro-inflammatory cytokines such as 
TNF-α. Therefore, TF plays a key role in mediating the interaction between inflammation and 
coagulation [65]. 
As a protective mechanism to prevent an uncontrolled pro-coagulant state, the body produces 
several factors to counteract the coagulation cascade. The most common factors are anti-
thrombin (AT), the protein C and protein S system and the tissue factor pathway inhibitor (TFPI) 
[65,94-96]. Protein C and its cofactor protein S play an important role in mediating the 
coagulation and inflammatory responses [65,93,94]. Protein C can inactivate factors which 
include Va and VIIIa and this inactivation delays the clotting cascade. Furthermore, protein C 
possesses anti-inflammatory properties by inhibiting the transcription factors NF-κB and AP-1 
[93,96]. During sepsis, protein C, protein S and AT are being depleted by the continuous 
activation of the coagulation pathway and therefore are present in very low levels [65,93,96]. 
Increased mortality has been shown to correlate with low levels of protein C in septic patients.   
In addition, during sepsis, the fibrinolytic system which is involved in mediating the removal of 
clots or thrombus from injured tissue once the homeostasis is restored,  is inhibited [7,94,96-99]. 
The two main inhibitors of this system are plasminogen activator inhibitor-1 (PAI-1) and 
thrombin activatable fibrinolysis inhibitor (TAFI). PAI-1 levels are increased in response to LPS 
thereby leading to impaired fibrinolysis further promoting coagulation [94,98].  
33 
 
The overwhelming immune response to the infection leads to an excess production of many 
inflammatory and non-inflammatory mediators as described above. These mediators collectively 
lead to cellular dysfunction. As a result, diffuse tissue injury in both affected and previously 
unaffected locations will occur. The combination of the uncontrolled inflammatory and 
coagulation responses will amplify the host response and result in tissue hypoxia and ischemia. 
Consequently, there will be deterioration of organ function and associated metabolic 
abnormalities potentially leading to death.  
1.12 Apoptosis 
Apoptosis is a highly regulated physiological process that serves to eliminate unwanted cells. 
This process, often referred to as programmed cell death, is critical during development and is 
necessary in maintaining homeostasis and to clear damaged or abnormal cells [99-103]. 
Apoptosis can be morphologically distinguished from other types of cell death by the presence of 
membrane blebbing, chromatin condensation, apoptotic body formation and DNA fragmentation 
[99,101-103]. Apoptosis is a conserved evolutionary mechanism that utilizes proteases called 
caspases to initiate and execute cell death [104].  
1.12.1 Caspases 
Caspases play a critical role in the initiation and execution of apoptosis. Currently there are 14 
mammalian caspases that have been identified [102,103,105]. Based on homology sequences, the 
family of caspases has been categorized into three subfamilies. These include the inflammatory 
mediators caspase 1, 4, 5, 11, 12, 13 and 14; the apoptosis initiators caspase 2, 8, 9 and 10; and 
the apoptosis executioner caspase 3, 6 and 7 [102,103,105,106]. Each member of the caspase 
family is constitutively expressed as proenzymes and contains 3 domains; an N-terminal 
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prodomain, a large subunit and a C-terminal small subunit [103,105]. Initiator caspases contain 
an extended N-terminal prodomain of >90 amino acids. In contrast, effector caspases have a 
smaller prodomain of approximately 20-30 amino acids [103]. The long prodomain in the 
initiator caspases contains sequence motifs that allow them to interact with adaptor molecules. 
For instance, caspases 8 and 10 contain two death effector domains (DED) whereas caspases 2 
and 9 contain a caspase-recruitment domain (CARD) [105,107]. Activation of caspases require 
dimerization and/or proteolytic cleavage [108,109]. For example, caspase 9 is generally present 
as monomers and must cluster through adaptors such as APAF-1 which is required for activation 
[102,104]. Proteolytic cleavage of caspases, which is generally required for their activation, are 
cleaved immediately following an aspartic acid residue [102]. This residue is located between the 
N-terminal prodomain and the large subunit as well as in the interdomain linker region 
separating the large and small subunits [102]. The initiator caspases will generally act upstream 
of the effector caspases [102,110]. An example of a caspase activated cascade is the activation of 
the initiator caspase 8 which leads to the activation of the effector caspase 3. A substrate of this 
effector caspase is DNA fragmentation factor (DFF) 45. In the inactive form, DFF 45 is 
complexed to the nuclease DFF 40 thereby inhibiting its activity [102,110,111]. Upon cleavage 
by caspase 3, DFF 45 releases DFF 40 and consequently allows DFF 40 to cleave chromatin. 
1.12.2 Inhibitors of Apoptosis 
Cells are able to negatively regulate the activity of caspases through a family of proteins called 
inhibitors of apoptosis (IAPs) [112]. Thus far, eight mammalian IAPs have been discovered 
including XIAP, c-IAP1, c-IAP2, ML-IAP/Livin, ILP-2, NAIP, Bruce/Apollon, and survivin 
[112-114]. These proteins inhibit apoptosis through several mechanisms, for example ligands 
and signal transducers in the TNF-α pathway may be blocked by these molecules [102]. In 
35 
 
addition, pro-apoptotic members of the Bcl-2 family as well as cytochrome c may be targeted 
and blocked by IAPs [102]. More importantly, IAPs may directly interact with caspases 3, 7 and 
9 [112,115]. For example, caspase 9 is primarily inhibited by a member of the IAP family called 
XIAP. Similarly, XIAP is the predominant inhibitor for caspases 3 and 7, however, other 
members of the IAPs such as c-IAP1 and c-IAP2 are also capable of inhibiting the caspase 
activity but to a lesser extent [103]. IAP family members are characterized by the presence of 
one to three copies of a baculoviral IAP repeat (BIR) domain [103,112]. XIAP, c-IAP1 and c-
IAP2 all contain three tandem BIR copies along with a RING zinc finger domain at their C-
termini [103,112]. Despite the presence of three BIR domains, data has shown that these 
domains are not equivalent in binding and inhibiting caspases. For example, XIAP’s BIR3 
domain potentially inhibits caspase 9 whereas the linker region between BIR1 and BIR2 inhibit 
caspase 3 and 7 [103,112,116,117]. RING domains which possess an E3 ubiquitin ligase activity 
have been shown to be essential in the targeted degradation by the ubiquitin-proteosome system 
[105,116]. Ubiquitin is covalently attached at a lysine residue of the target protein. The addition 
of one ubiquitin (monoubiquitination) results in the subcellular localization of the protein. The 
addition of oligomeric ubiquitin chains (polyubiquitination) results in protein degradation by the 
26S proteosome. Ubiquitination is accomplished through a series of steps starting with ubiquitin 
conjugation to E1, E2 and finally being transferred to the target protein by E3 (ubiquitin ligase 
enzyme) [115-119]. Therefore, IAPs are able to self target for degradation [115]. For example, 
the C-terminal RING domain will initiate polyubiquitination at a lysine residue in the XIAP 
polypeptide. Therefore, XIAP’s autoubiquitination would hinder its function of inhibiting 
apoptosis and allow cell death to occur more readily. In addition, IAPs are also able to degrade 
other proteins which include caspase 3 and Smac/DIABLO [115,116]. c-IAP1 and c-IAP2 also 
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possess a CARD domain near their RING zinc finger domain which suggests a possible CARD-
CARD interaction between c-IAPs and caspases. In summary, IAPs are able to inhibit apoptosis 
either by binding, inhibiting or degrading caspases.  
1.12.3 Intrinsic Pathway 
There are two main pathways for the activation of caspases; the intrinsic pathway and the 
extrinsic pathway. The intrinsic pathway also known as the mitochondrial pathway is activated 
by intracellular stimuli such as DNA damage (p53), nutrient starvation and growth factor 
withdrawal [102,103,108]. The mitochondrial pathway serves as an amplification mechanism for 
the receptor mediated apoptosis. The key element in this pathway is the release of pro-apoptotic 
factors from the mitochondria which include cytochrome c and apoptosis inducing factor (AIF). 
When these factors are released, a cytosolic complex called the apoptosome will form in the 
presence of dATP which consists of cytochrome c, apoptotic protease activating factor-1 (Apaf-
1) and procaspase 9 [102,104,108]. More specifically, cytochrome c will bind to the cytosolic 
protein Apaf-1 and cause a conformational change which leads to Apaf-1 activation. The Apaf-
1/cytochrome c will oligomerize into a heptameric structure similar to a wheel in the presence of 
dATP. The centre of the heptameric structure contains seven N-terminal CARD domains which 
interacts with the CARD domains of individual procaspase 9 molecules [104]. The proximity of 
procaspase 9 molecules will lead to dimerization and activation of caspase 9. In turn, procaspase 
3 will be recruited to the complex where caspase 9 will cleave the effector caspase into its active 
form. Caspase 3 will complete the execution phase of apoptosis by cleaving its substrate DFF 45 
and allowing the nuclease to fragment the chromosomal DNA [102,104].  
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1.12.3.1 Bcl-2 Family 
Important regulators of the mitochondrial pathway are the members of the Bcl-2 family which 
serve as gatekeepers for the mitochondria [103]. Also, they play an essential role in the crosstalk 
between extrinsic and intrinsic pathways to amplify the response [103,120]. To date, more than 
two dozen members have been categorized as belonging to the Bcl-2 family [103]. All members 
contain at least one of four characteristic Bcl-2 homology domains (BH1-BH4) [102,121,122]. 
According to their structure and function, the Bcl-2 proteins are divided into three categories: 1) 
pro-survival including Bcl-2, Bcl-XL, Bcl-w, Mcl-1, A1 (Bfl-1), NR-13 and Boo (Diva) contain 
all four BH domains [102,107,123]. These anti-apoptotic proteins are inhibitors of Bax/Bak. This 
inhibitory action is accomplished by either direct binding to Bax/Bak, prevention of Bax/Bak 
binding to mitochondrial proteins or by counteracting the effects of Bax/Bak on the mitochondria 
[107,121]; 2) pro-apoptosis including Bax, Bak and Bok (Mtd) which share sequence homology 
to Bcl-2 in the BH1, BH2 and BH3 domains [102,107,123]. These proteins exist as monomers 
but upon stimulation, will homo-oligomerize and form pores on the mitochondrial membrane 
thereby allowing the release of apoptotic factors such as cytochrome c [103,107,121]; 3) BH3-
only family including Bid, Bim, Bad, Bik, Blk, Hrk (DP5), Bnip3, BimL, and Noxa contain the 
BH3 domain and exhibit pro-apoptotic activity [122]. BH3-only proteins will act mainly by 
binding and neutralizing the pro-survival proteins Bcl-2/Bcl-XL. The inhibition of Bcl-2/Bcl-XL 
will allow the activation of Bax/Bak and trigger mitochondrial permeabilization [102,121-123]. 
The members of the BH3-only family are activated by a variety of stresses. For example, Bid, 
Bad and Bim are activated by death receptors/caspase 8, glucose deprivation and cytokine 
withdrawal, respectively [107]. According to the rheostat model, the levels of Bcl-2/Bcl-XL 
versus Bax/Bak are at the core of the cell’s decision to survive or die [107].  
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1.12.3.2 Smac/DIABLO 
Smac/DIABLO (second mitochondria-derived activator of caspase/direct IAP-binding protein 
with low pI) is a protein that is normally localized to the mitochondria. After exposure to lethal 
apoptotic stimuli, Smac/DIABLO is released into the cytosol from the mitochondria with 
cytochrome c and mediates apoptosis [103,114]. Cytochrome c activates Apaf-1 whereas 
Smac/DIABLO promotes caspase activation by associating with the apoptosome and by 
negatively regulating the IAPs. Smac/DIABLO binds to IAPs thereby preventing the IAP-
caspase interaction [103]. For example, Smac/DIABLO binds to the BIR3 domain of XIAP 
[105]. Since Smac/DIABLO has a dimeric scaffold, it can bind more tightly to XIAP as opposed 
to the monomeric caspase 9 protein [103]. Consequently, Smac/DIABLO-XIAP complex 
undergoes ubiquitination and proteosome degradation resulting in significant XIAP depletion 
and allows for caspase activation [103]. In addition, evidence has been provided that implicates 
Smac in TNF-α-mediated caspase 8 activation [124].  
1.12.4 Extrinsic Pathway 
The extrinsic pathway is activated by binding of an external stimulus such as Fas ligand (FasL) 
and TNF-α to its cognate cell surface receptor [107]. These death ligands are homotrimeric and 
thus cause oligomerization of the receptors upon ligand binding. The receptors contain a death 
domain (DD) in their intracellular region which will form homotypic interactions with adaptor 
proteins such as Fas-associated death domain (FADD) and TNFR-associated death domain 
(TRADD) [102,107]. Subsequently, these receptor-associated adaptor molecules will aggregate 
and recruit initiator caspases, such as caspase 8 or 10 through their common DED. For example, 
FasL binding to its receptor Fas will cause a conformational change on the cytoplasmic region of 
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the receptor. The DD of Fas will interact with the DD of FADD. FADD also contains a DED and 
thus is thought to interact with the prodomain of procaspase 8 which contains two DEDs. 
Consequently, procaspase 8 will oligomerize and therefore complete the formation of the 
multicomponent death-inducing signal complex (DISC) [107,108]. Caspase 8 is possibly 
activated in the DISC by an induced proximity model. This model is based on the theory that a 
high concentration of procaspase 8 will lead to autoproteolysis and subsequent activation of the 
caspase cascade [102,107,108]. TNF-α signalling involves the formation of two complexes based 
on a temporal manner as previously described. Complex I comprised of TNFR1, TRADD, 
TRAF2, RIP1, and cIAP1 will form upon TNF-α binding to its receptor. TRADD-based complex 
dissociation from the receptor leads to the recruitment of the FADD and procaspase 8 formation 
of Complex II [70]. The balance between complex I and complex II is potentially regulated by a 
protein called c-FLIP [70]. c-FLIP is expressed by NF-κB through the activation of complex I. c-
FLIP is a caspase 8 inhibitor since it is structurally similar to caspase 8 but lacks the proteinase 
site [70,102,108]. Therefore, c-FLIP can be recruited to the complex but is not able to transduce 
the death inducing signal. Thus, complex II is able to actively participate in cell death when NF-
κB activation is inadequate. Activation of caspase 8 leads to the cleavage of downstream effector 
caspases such as caspase 3 which ultimately leads to DFF 40 activation. 
The extrinsic pathway will require the activation of the intrinsic pathway for an amplification 
mechanism in certain cell types. In Type I cells, the production of caspase 8 is sufficient to 
activate caspase 3 and the cell is able to directly undergo apoptosis. In Type II cells, the amount 
of FADD being recruited is very low resulting in a limited amount of active caspase 8 [139]. 
Therefore, the extrinsic pathway will require the involvement of the mitochondria to execute 
apoptosis. The crosstalk between these two pathways is dependent in part on the cleavage of the 
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Bcl-2 family member called Bid. Cleavage of the BH3 domain of Bid will release a proapoptotic 
fragment called truncated Bid (tBid) [120]. Subsequently, Bax/Bak will homo-oligomerize and 
allow the release of proapoptotic factors such as cytochrome c ultimately leading to the 
formation of the apoptosome and subsequent cell death. 
1.13 Apoptosis and Sepsis 
Apoptosis is a process that has been shown to be misregulated during sepsis and septic shock 
[140-145]. Factors including reactive oxygen species (ROS), endotoxin, Fas ligand and cytokines 
(TNF-α, IL-1β, IFN-γ, IL-8, IL-16 and IL-10) are important mediators of the apoptotic cascade 
[109,141,146]. For example, treatment of cardiac myocytes with cytokines led to apoptosis of 
these cells [147]. More specifically, TNF-α was added at increasing concentrations ranging from 
1 to 4 nmol to adult rat cardiac myocytes. These results showed a correlation between increasing 
TNF-α concentration and increased apoptosis as measured by comet, tunnel and genomic DNA 
laddering experiments [147]. In addition, Ing et al. also observed that cytokines induce 
apoptosis. A combination of TNF-α (25 ng/mL), IL-1β (5 ng/mL) and IFN-γ (100 U/mL) were 
used to treat neonatal cardiac myocytes which resulted in apoptosis as determined by propidium 
iodide staining, genomic DNA laddering and PARP cleavage [148]. In addition, the synergistic 
combination of cytokines induced apoptosis in a NOS dependent fashion since this effect was 
reversible in the presence of the iNOS inhibitor N-methyl arginine (NMA) [148].  
Evidence of apoptosis is also observed in cells of the immune system, intestine, liver and lung in 
experimental live-infection studies of sepsis [149-152]. Genomic DNA laddering was apparent in 
the liver, lung, kidney and caecum of an endotoxin shock mouse model of sepsis where LPS was 
injected at a concentration of 5 mg/kg [153]. A confirmatory tunnel assay was employed to 
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reveal LPS induced apoptosis in the liver. Hotchkiss et al. utilized a cecal ligation and puncture 
model of sepsis to report increased lymphocyte apoptosis in the thymus, spleen, ileum, colon, 
lung, kidney and muscle. Furthermore, Hotchkiss and colleagues showed that apoptosis in 
lymphoid organs is related to poor outcome in their animal model of sepsis [109,154]. Systemic 
administration of caspase inhibitors as well as overexpression of the Bcl-2 gene led to an 
increase in survival rate and decreased apoptosis in the thymus and spleen as determined by 
DNA laddering and tunnel assay [154]. Neviere et al. reported a 3-fold increase in rat myocyte 
apoptosis and activation of caspase 3, 8 and 9 in an endotoxic shock animal model [155]. Carlson 
and colleagues recently reported that LPS induces a TNF-α dependent caspase cascade to 
mediate cardiac apoptosis. Carlson et al. performed an experiment which involved the injection 
of  4 mg/kg of LPS to the intraperitoneum of mice and detected cardiac apoptosis contributing to 
the cardiac dysfunction [156]. Similarly, Lancel et al. reported that endotoxin induced 
myocardial dysfunction which utilized the death receptor pathway using a rat model of sepsis. 
Overexpression of Bcl-2 prior to LPS administration prevented myocardial dysfunction in rats 
[157]. Burn injury, similarly to septic shock,  is associated with elevated levels of circulating 
pro-inflammatory cytokines and reversible myocardial depression [158,159]. Lightfoot et al. 
reported a marked increase in apoptotic cells in the left ventricle of the adult rat heart 24 h and 
48 h after burn trauma. The increasing level of myocyte apoptosis was correlated to a decrease in 
cardiac function [158].  
Administration of pan-caspase inhibitors has improved survival by 40-45% in experimental 
animal models [160]. Oberholzer et al. reported that local injections of a specific caspase 9 
inhibitor, Z-LEHD-fmk, into thymi of septic mice led to increased survival [161]. Further, 
introduction of broad spectrum caspase inhibitors z-VAD.fmk and z-DEVD.cmk 2 h post 
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endotoxin challenge led to improved endotoxin-induced myocardial dysfunction, reduced 
caspase activation and reduced myocyte apoptosis [162]. In addition, intratracheal administration 
of short interfering RNA (siRNA) directed against Fas (Fas-siRNA) in a septic mouse model 
decreased pulmonary apoptosis and neutrophil infiltration [163]. In vivo delivery of siRNA 
targeted against Fas or caspase 8 in a CLP mouse model of sepsis led to an increased survival of 
50% with a maintained suppressive effect for up to 10 days [160,164].  
Human studies of septic shock have suggested increased apoptosis primarily in cells of the 
immune system although the phenomenon has also been noted in intestinal epithelial cells 
[145,160,166-168]. Despite the fact that overt increased myocyte apoptosis has not been reported 
in the heart in spontaneous disease or in live infection models of sepsis and septic shock, recent 
publications suggest that preapoptotic signalling may occur contributing to myocyte cellular 
stress and cytopathic changes in the heart leading to depressed myocardial contractility 
[145,157,165]. Therefore, widespread preapoptotic signalling may be implicated in the 
pathogenesis of septic shock by causing cellular dysfunction which progresses to organ failure 
including myocardial depression. 
1.14 Influenza and Sepsis 
Influenza A is a negative sense single stranded RNA virus that belongs to the Orthomyxoviridae 
Family. This enveloped virus contains 8 segments of viral RNA which encodes 11 viral proteins. 
Influenza A infects humans and is the causative agent of the flu. Annually it infects 
approximately 5 to 15% of the population worldwide and results in an estimated 250 000 to 500 
000 deaths a year. The nature of influenza A replication results in a high mutation rate which 
results in the need for seasonal vaccinations. In addition the zoonotic nature of the influenza 
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virus allows for recombination of viral segments from different strains creating new variants that 
have not been encountered before. This type of mutation is the method by which pandemic 
strains of the flu arises.  Infection with influenza results in a respiratory illness that for most 
individuals is self-limiting. However in susceptible populations which include individuals with 
pre-existing pulmonary or cardiac conditions, the very young and the elderly fatal complications 
may arise. The most serious of these is the development of viral pneumonia which may be 
accompanied by secondary bacterial infections. Progression of pneumonia leads to the 
development of acute respiratory distress syndrome (ARDS), acute lung injury (ALI) and 
potentially respiratory failure. This progression is a combined effect of the host immune system 
response to influenza infection and the viral infection itself.   
1.15 Influenza A Transmission 
The influenza A virus results in 3 to 5 million severe cases globally each year. In the United 
States the Centre for Disease Control estimated over a 30 year period from 1976-77 season to 
2006-2007 season there were an average number of deaths of 23,607 per year.  Interestingly the 
range of influenza associated deaths over this period varied from a low of 3,349 to a high of 
48,614 deaths. This highlights the variable nature and pathogenicity of different influenza strains 
[181]. The authors of this report also noted that seasons where H3N2 was prominent, the deaths 
associated with influenza was 2.7 times higher than in seasons where other strains were 
prominent. The variability of different strains also plays a role not only in the pathogenicity of 
influenza but also in its ability to be transmitted from person to person [181]. The influenza A 
virus is responsible for seasonal epidemics and infrequently global pandemics of the flu as was 
the case with pandemic H1N1 in 2009. Seasonal outbreaks of the flu are a result of continual 
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mutation of this virus with regards to the proteins recognized by the immune system while 
pandemic strains result from antigenic shifts which completely change the viral proteins the 
immune system responds to. H1N1 is estimated to be responsible for approximately between 
151,700 and 575,400 deaths globally [182]. Although the risk factors for development of severe 
complication from the flu were similar between seasonal and H1N1 infections for individuals 
with chronic lung diseases, pre-existing cardiac disease and pregnancy they differed in that 
obesity and people of younger ages cohorts (younger than 65) developed greater complications 
with H1N1 then those with seasonal strains [183]. 
The influenza virus is transmitted by three main modes which are 1) direct contact with an 
infected fomite 2) inhalation of droplets and 3) small particle aerosols. Infected droplets are 
spread primarily through coughing while aerosols are created during sneezing, speaking or 
breathing [184]. Infected aerosols with particle sizes below 5 µm have been shown to remain 
aerosolized for 1 hour [185]. To spread from one person to the next the influenza virus must 
remain viable while in the aerosol or on inanimate objects [186]. Viability of influenza outside of 
the body has been studied and factors affecting the viability of this virus have been identified. 
Relative humidity is one factor studied. The highest viability was associated with humidity levels 
close to 100% which mimics the levels within the respiratory system [187]. Infectious aerosols 
released in the air where the relative humidity ranged from 50% to 84% displayed a steady 
decrease in viability. When the humidity level dropped below 50% viability of the influenza 
virus increased [187]. The variation of viability was associated with aerosol dehydration caused 
by relative humidity levels which increased the salt concentration to a threshold range where the 
protein content of respiratory aerosols protected the virus from further decline in viability  [188]. 
The changes in humidity are also associated with the different seasonal activities of influenza 
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over different regions of the globe. Temperate climate regions generally experience high 
influenza activity during the times of lowest humidity and coldest temperatures while tropical 
regions experience influenza peaks during their rainy season where the humidity levels are close 
to 100%. In both regions the tendency of people to congregate indoors also corresponds to this 
timing [189]. 
Infection with influenza A virus results in developing the flu. The symptoms of a typical 
uncomplicated influenza infection are fever, chills, rhinorrhea, nasal congestion, sinus pain, sore 
throat, cough, headache, anorexia and myalgia [190]. The influenza virus generally does not 
directly cause these symptoms but triggers an immune response that causes their development 
[191]. Macrophages continually monitor the epithelium of the airways. In the presence of the 
influenza virus macrophages become activated and trigger the acute phase response. Release of 
chemokines from activated immune cells further recruits more immune cells to the infected 
tissue resulting in inflammation that triggers systemic symptoms associated with the flu [190]. 
Fever is the most common symptom of the flu and is caused by the response to the release of 
cytokines including TNF-α, IL-6 and IL-1 [191]. These cytokines whether they are produced 
locally in the lung or systemically produce the systemic effect of fever. These cytokines cross the 
blood brain barrier reaching the central nervous system. There they interact with the vagus nerve 
and signal to the temperature control area of the hypothalamus. This initiates signalling pathways 
that results in the hypothalamus releasing mediators that cause reflex shivering, peripheral blood 
vessel constriction that results in the sensation of chills. The sensation of sore throat is attributed 
to the production of bradykinins and prostaglandins in the airways [190].  
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1.16 Influenza A Viral Structure 
The influenza A virus is a negative sense segmented RNA virus that contains a lipid envelope. 
The core of the virus particle contains 8 segments of viral RNA that are coated by a viral protein 
nucleoprotein (NP) [192,193]. The protein coated segments are also bound to the three protein 
subunits polymerase basic 1, polymerase basic 2 and polymerase acidic (PB1, PB2, PA) that 
comprise the viral RNA dependent RNA polymerase which is responsible for both transcription 
and replication of the viral genome [1194]. Together these are the components of the viral 
ribonucleoproteins (vRNP) which are surrounded by a protein layer made from the viral protein 
matrix protein 1 (M1) [195]. This protein shell is covered by the envelope which is a lipid bilayer 
derived from the host cell membrane. The envelope contains three viral proteins hemagglutinin 
(HA), neuraminidase (NA) and matrix protein 2 (M2). The lipids of the envelope are enriched 
with sphingolipids and cholesterol forming rafts [186]. These raft domains associate with the 
embedded envelope proteins HA, NA and M2. The stability of the virus particle is primarily 
governed by the lipids of the membrane. The envelope proteins HA and NA have a low mobility 
with in the envelope and reinforce the virus structure through their association with the 
underlying M1 protein. M1 links the vRNPs to the envelope glycoproteins contributing to an 
overall stabilizing effect of the virus structure [187]. 
The virus gains access to the body through the nose, mouth or eyes. Influenza A virus initiates an 
infection when it comes in contact with the mucosal surfaces of the respiratory tract. Influenza A 
must come in direct contact with the epithelial cells of the respiratory tract to initiate an 
infection. Here the virus encounters its first barrier, the layer of mucus that covers and protects 
the epithelial cells of the respiratory tract. The envelope glycoprotein NA cleaves sialic acid 
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from mucin that lines the epithelial cells. The virus attaches to the exposed cells by the second 
envelope glycoprotein HA. The HA protein forms a homotrimer in the envelope. The monomer 
of HA is composed of two polypeptides termed Ha1 and Ha2. Ha1 possess the receptor binding 
domain while Ha2 contains the membrane fusion peptide [198]. This protein attaches to sialic 
acid linked glycoproteins on the surface of epithelial cells. The type of sialic acid linkage to the 
glycoprotein determines the tropism of the different types of influenza A viruses towards 
different hosts [199]. Human influenza A viruses contains a HA which has a binding preference 
for an α-2,6 linked sialic acid to galactose whereas the avian origin influenza HA has a binding 
preference for an α-2,3 linked sialic acid to galactose. The distribution of these glycosidic 
residues within a species also determines the tissue tropism of influenza. The human respiratory 
tract contains predominantly α-2,6 linkages expressed on the surface of the epithelium. HA also 
is a major determinant for tissue tropism of influenza [184]. HA must be cleaved in order for it to 
be functional. Proteases found ubiquitously expressed in the lungs are able to cleave HA in to a 
functional viral protein. Strains of influenza possessing HA that can be cleaved by other classes 
of proteases are able to disseminate, infecting a larger range of tissues and tend to be more 
pathogenic [199]. In addition to sialic acid binding recent studies have identified alternative 
modes of influenza A entry into cells that are dependent on c type lectins and independent of 
sialic acid binding [200]. Other requirements for influenza A viral attachment are also being 
elucidated. Fibronectin an extracellular matrix protein has been identified as a requirement for 
certain strains of H1 and H3 influenza viruses. Binding of the virus to the cell surface induces 
uptake through endocytosis. This uptake has been shown to utilize clatherin dependent and 
caveolin dependent mechanisms [201]. Once the virus is endocytosed it remains in the maturing 
endosome. Influenza escapes the endosome in a pH dependent manner [202]. As the endosome 
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matures it acidifies which activates the M2 envelope protein. The M2 protein is a tetramer 
integral protein that forms a proton selective ion channel. This protein contains three major 
domains, a short ectodomain, a transmembrane domain that forms the ion channel and a long 
cytoplasmic domain [203]. Activation of M2 allows protons to enter the viral particle. At a 
critical pH the M1 protein that stabilizes and mediates attachment of the vRNP to the envelope 
proteins dissociates and undergoes a morphological change freeing the vRNP from the envelope. 
In addition the Ha2 peptide of the HA protein activates allowing for the fusion between the 
membrane of the endosome and the viral envelope. This fusion allows for the cytosolic release of 
the vRNP from the endosome [204]. Once inside the cytoplasm the vRNP must enter the nucleus 
for transcription of viral genes and replication of the viral genome [205]. Entry of the infecting 
vRNP is mediated by NP which possesses a nuclear localization sequence that binds with 
karyopherin which is an endogenous heterodimer of karyopherin α1 with karyopherin β or 
karyopherin α2 and karyopherin β. Once bound by karyopherin the vRNP is ferried to and 
docked at the nuclear pore complex. Entry in to the nucleus is Ran 10 and p10 dependent [206]. 
Once in the nucleus transcription of the viral genes occurs. The mechanism of viral transcription 
and genome replication has been well studied but the regulation and switching from transcription 
to genome replication remains to be fully elucidated. Progress has been made with regards to 
identifying viral elements involved in regulating these processes. Umbach et al. have found that 
influenza A virus produces short RNA nucleotides ranging from 18 to 27 nucleotides in length. 
These viral leader RNAs were found to originate from each of the 8 segments 5’ ends [207]. 
Perez et al. found that these virally encoded RNAs acted as enhancers for viral replication but 
they did not function as a primer for replication. These short RNAs were retained in the nucleus 
throughout the infection and it is postulated that they act to not only stabilize viral RNA genome 
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replication but to also play a role in maintaining the proper stoichiometry of each viral segment 
[208]. Viral proteins also have been shown to regulate viral transcription and genome replication. 
Widjaja et al. produced a model whereby transcription of viral genes is accomplished by the 
associated RNA dependent RNA polymerase. Production and nuclear accumulation of new 
polymerase allows for complementary RNA to be made. This serves as a template for viral 
genome replication which is stabilized by both the newly synthesized polymerase and 
nucleoprotein [209]. They also identified elements of the 3’ and 5’ UTR of the viral segments 
involved in competition for viral proteins required for replication and also demonstrated that 
shorter viral segments can out compete larger segments for viral proteins [209]. The viral 
genomic RNA is associated with viral nucleoprotein and the three polymerase subunits before 
being exported out of the nucleus. This requires the re-import of translated nucleoprotein and the 
polymerase subunits which possess multiple elements that allow for shuttling between the 
nucleus and cytoplasm [210]. Together these proteins form the vRNP. The vRNP forms a 
complex in the nucleus between the M1 protein and the nuclear export protein (NEP) formerly 
known as NS2 [211]. Both M1 and NEP have been shown to be required for export of the vRNP 
out of the nucleus into the cytoplasm which is chromosome region maintenance I (CRM1) 
dependent [212]. The vRNPs accumulate at the microtubule organizing centre upon exiting the 
nucleus. In addition to these viral proteins, a host cell protein Y-box binding protein (YB-1) has 
been identified as associating with this complex in the nucleus. This protein is believed to act as 
an adaptor for the vRNP allowing it to associate with microtubules and to target it to the rab11a 
recycling endosome which delivers the vRNP to the site of virus assembly [212].  
Release of the virus from the cells requires assembly of the viral proteins and all 8 vRNP 
segments into the viral particle. This assembly occurs at the cell’s plasma membrane. The viral 
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proteins HA, NA and M2 are transmembrane proteins that are inserted into the host’s plasma 
membrane [213]. HA and NA are localized to lipid rafts rich in cholesterol and sphingolipids 
[214]. The M1 protein forms associations with the cytoplasmic portions of these transmembrane 
proteins. It has been demonstrated that viral assembly is selective for each of the 8 vRNPs and 
virions have one copy of each segment in them [213]. Initiation of the budding process involves 
the HA protein which appears to be necessary for efficient budding but is not absolutely 
required. It has been shown that HA assists in creating membrane curvature to start the bud but 
requires the recruitment of other viral proteins for the budding process to complete. The M2 
protein plays a role in the scission of the bud from the cell. It has been shown that M2 
accumulates in the neck of the bud where scission occurs. Scission of the bud occurs 
independently of the host endosomal sorting complex required for transport (ESCRT) [215]. 
Final release of the virus particles requires the enzymatic action of NA which cleaves the sialic 
acid moiety from the budding virus freeing it from the cell. 
1.17 Viral Pneumonia 
One of the most serious complications of influenza A infections is the development of 
pneumonia. Viral induced pneumonia is a result of a combination of extensive viral replication in 
the lung, particularly the lower regions and the host immune response to the virus [216]. The 
general progression to viral pneumonia development starts with viral replication in the lung 
epithelial cells and alveolar epithelium. Detection of viral infection in the epithelial cells induces 
the production and release of pro-inflammatory cytokines and chemokines [217]. The host 
response to the release of these inflammatory mediators is the recruitment and activation of 
leukocytes from the circulatory system into the lung. In combination with resident alveolar 
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macrophages the infiltration of mononuclear cells can lead to the overproduction of pro-
inflammatory cytokines [218]. Cell damage results from both the replicating virus which induces 
both necrosis and apoptosis in lung epithelial cells and macrophages and the products from 
activated leukocytes including reactive oxygen species [219]. When the cell damage becomes 
extensive this leads to alveolar flooding where protein rich fluid accumulates in the airspace due 
to impaired fluid uptake from the alveolar epithelium [220]. This edema is further exacerbated 
by an increased permeability of the lung capillaries in response to the infiltrating leukocytes. 
Damage to the blood air barrier results in decreased gas exchange which results in systemic 
hypoxia. Autopsy examination of lung tissue from influenza induced pneumonia shows signs of 
edema, hemorrhage, diffuse alveolar damage and the production of hyaline membrane [183]. 
Acute respiratory distress syndrome (ARDS) leading to respiratory failure is the most common 
lethal development of influenza induced pneumonia.  This syndrome is divided into three phases, 
the exudative, inflammatory and fibroproliferative phase [221]. Damage to sufficient numbers of 
type II pneumocytes from influenza infection results in a decrease of surfactant production in the 
lung. Lung surfactant has been shown to have immunomodulating effects on immune cells [222] 
. It has been demonstrated that during ARDS decreased lung surfactant results in increased PI3 
kinase activity in immune cells [223]. On lung epithelial cells and alveolar macrophages the 
decreased surfactant production results in increased AKT activation. For neutrophil dependent 
damage to the lung AKT activation has been shown to be involved [224]. The ensuing alveolar 
flooding is a result of the impaired fluid removal across the lung epithelium due to impaired 
sodium transport across alveolar epithelial cells [221]. In addition the increased cytokine and 
chemokine production of the alveolar epithelium increases the permeability of the lung 
endothelium allowing for increased fluid to enter the alveolar space [224]. A further 
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complicating factor with influenza induced pneumonia is the development of a secondary 
bacterial infection in the lungs [225]. Up to half of pandemic influenza induced pneumonia was 
associated with a secondary bacterial infection [226]. There is also an association with the type 
of bacteria found coinfecting with influenza A. Most commonly associated bacterial species 
which have been found to cause secondary infections to influenza are Streptococcus 
pneumoniae, Haemophilus influenza and Staphylococcus aureus [227]. For these species of 
bacteria there is an apparent synergism with regards to virulence and pathogenicity. Coinfection 
with influenza or preinfection with influenza virus results in changes to the functioning of 
immune cells particularly neutrophils and alveolar macrophages [228]. There is also an observed 
increase in bacterial adherence to the lung epithelium and a concurrent immunosuppression 
attributed to influenza infection [229]. It has been observed in mice that influenza infection 
results in higher cytokine production of TNFα, IL-1β, IL-6, MIP1α and KC relative to a sole 
bacterial infection [230]. Although influenza A infections predisposes the host to secondary 
bacterial pneumonia, a recent study has demonstrated that a previous infection with influenza 
affords some protection against subsequent bacterial pneumonia infection with a different 
influenza type. This protection was attributed to non-neutralizing antibody production from the 
initial infection against conserved internal viral protein NP [230].  
1.18 Influenza A Induced Pro-inflammatory Cellular Signalling 
Dendritic cells and macrophages, which reside in close proximity to the lung epithelium produce 
a significant amount of TNF–α and type I IFN in response to influenza virus infection [231]. 
These cytokines activate intracellular signal transduction pathways in the lung epithelial cells. 
The highly pathogenic 1918 Influenza virus induced gene expression profiles in mouse and non-
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human primate lungs which consisted of suppression of type 1 interferon antiviral response and 
enhanced expression of TNF- α, IFN-γ and IL-6 pro-inflammatory response. There is a dramatic 
increase in chemokines and inflammatory influx consisting of neutrophils, macrophages and T 
lymphocytes resulting in enhanced lung injury by a recombinant virus containing 1918 influenza 
genes HA and NA [232,233].  Interferons activate intracellular Jak-Stat pathway as well as 
alternative signal transduction pathways in parallel [234,235],  TNF- α activates a variety of 
protein kinases including c-Jun N-terminal kinase (JNK), extracellular-signal regulated kinases 
(ERK1/2), p38 and I-kappa B kinases (IKK). TNF- α activates nuclear factor kappaB (NF-κB) 
by means of a kinase relay module, involving the IκB  kinase (IKK) α, β, γ signalosome [236]. In 
addition to NF-κB, TNF- α also activates additional transcription factors such as AP1 (Fos-Jun) 
via JNK and activation transcription factor–2 (ATF-2) via JNK, ERK and p38 MAP kinase 
pathways [237-239]. Involvement of ERK, JNK, p38 MAP kinases and activation of 
transcription factors AP1, NF- B and ATF-2 has been described in response to influenza virus 
infection [240-244]. Thus, multiple MAP kinase pathways are activated by cytokines as well as 
virus replication. Influenza virus propagation was impaired by inhibition of Raf/Mek/ERK 
pathway [240]. Furthermore, lung-specific expression of active Raf kinase resulted in increased 
mortality of influenza virus infected mice [241]. Targeting of NF-κB pathway for antiviral 
therapy in influenza infection has been shown to reduce viral titers and cytokine expression 
[245]. Further understanding of intracellular signal transduction pathways may lead to the 
development of specific inhibitors of influenza viral replication as well as inflammatory host 
response that are involved in lung injury. 
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1.19 Intracellular Detection of Influenza A Virus. 
Cells of the lung epithelium have evolved receptors to detect the presence of viral nucleic acid 
and initiate a signalling cascade to induce an antiviral pro-inflammatory state (Figure 3). These 
receptors belong to a family of pattern recognition receptors each of which have a class of 
molecular structures which binds and activates them [246]. Influenza A virus has been 
demonstrated to activate toll-like receptors (TLRs), NLRP3 inflammasome which belongs to the 
NOD-like receptors, RIG-I like receptors (RLR), PKR and 2’-5’-oligoadenylate synthetase 
[247].  Activation of these receptors is the primary signal for production of pro-inflammatory 
cytokines and chemokines which are released to recruit and activate leukocytes from the 
circulation to the site of influenza infection [248,249]. The RLRs includes three members, 
retinoic acid inducible gene one (RIG-I), melanoma differentiation associated gene 5 (MDA5) 
and laboratory of general physiology 2 (LGP2). For cytosolic detection of influenza RIG-I is the 
primary receptor involved [250]. The vRNP and replicative intermediates contain 
5’triphosphates and double stranded RNA which are the unique viral molecular patterns that this 
receptor binds to distinguishing foreign viral RNA from self RNA [251]. Activation of RIG-I 
results in a cascade of signaling events that pivots around the association with the mitochondrial 
outer membrane embedded protein IPS-1 [250]. Subsequently the downstream signalling leads to 
the activation of transcription factors NFκB and interferon regulatory factors 3 and 7 (IRF).  
NFκB activation is responsible for the induction of transcription for pro-inflammatory cytokines 
while IRF3 and 7 induce the transcription of interferon beta gene which leads to the induction of 
antiviral genes to create an antiviral state [252,253]. Similar to RIG-I signalling activation of 
TLR3 which is a receptor that resides in the endosomal membrane results in the activation of 
NFκB and the production of pro-inflammatory cytokines [254]. TLR3 binds double stranded 
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RNA. Unlike RIG-I in pulmonary epithelial cells this receptor does not contribute significantly 
to the production of interferon however its signalling significantly induces a pro-inflammatory 
state [255]. In a mouse model of influenza induced pneumonia tlr3 negative mice were found to 
have a protective effect with reduced mortality compared to wild type mice with increased 
survival being attributed to a decreased production of pro-inflammatory cytokines [254]. PKR is 
a 68 kDa latent protein expressed by most cells. It is induced by interferons and is activated by 
the binding of double stranded RNA or double stranded structures within ssRNA [256]. PKR 
possess two double stranded RNA binding domains which binds its RNA ligand. Binding of 
RNA induces a conformational change that allows for monomeric PKR to form dimers which 
allows for autophosphorylation and activation of its kinase domain [257]. Once activated PKR 
will phosphorylate its substrate eIF2α initiating a stress response in the cell [258]. This stress 
response is a rapid reversible inhibition of protein translation. This reduction in translation leads 
to a reduced translation of all mRNA. The accumulation of mRNA with in the cytoplasm triggers 
the recruitment of three proteins; the cytotoxic granule associated RNA binding protein (TIA-1), 
TIA-1 cytotoxic granule associated RNA binding protein like 1 (TIAR) and GapSH3 domain 
binding protein (G3BP) [259]. As these proteins bind the mRNA they trigger aggregation of 
these complexes together forming stress granules.  PKR triggered inhibition of translation leads 
to the formation of these antiviral stress granules. Viral induced stress granules require PKR 
activation. Influenza induced stress granules recruit PKR, RIG-I, and oligoadenylate synthetase 
(OAS) [260]. This platform provides an efficient mechanism for interferon induction in response 
to viral infection. It has also been shown that vRNA colocalizes with these granules which 
activates RIG-I. Once activated the antiviral stress granule is recruited to the mitochondria to 
associate with IPS-1. The viral NS1 protein has been shown to antagonize interferon induction at 
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many levels. This viral protein inhibits activation of PKR, OAS, and RIG-I [261]. Through 
inhibition of PKR activation influenza A virus prevents antiviral stress granule formation and 
production of interferons while the proinflammatory arm of signalling remains intact. The 
OAS/RNAse L system is part of the innate immune response. OAS is a pattern recognition 
receptor that is activated by viral double stranded RNA [262,263]. Activation of OAS leads to 
the production of a unique molecule 2’,5’ oligoadenylate. This molecule specifically activates 
RNAse L [264]. Typically OAS produces trimers and tetramers of 2’,5’-oligoadenlyate. 
Activation of RNase L requires the formation of dimers in response to binding of 2’,5’-
oligoadenlyate. The active dimer cleaves single stranded RNA at the dinucleotide motif of uracil 
adenosine or uracil uracil [265]. The resulting cleavage product possesses a 3’ phosphate which 
acts as a substrate for RIG-I thus amplifying the signalling to interferon production [247,266]. In 
addition the degradation of viral RNA coupled with the inhibition of translation is the main 
mechanism of RNase L antiviral activity. However RNase L is not specific to viral RNA 
degradation and it degrades host rRNA and mRNA and can lead to apoptosis. The NS1 protein 
of Influenza A has evolved to inhibit the action of the OAS/RNase L system [261]. NS1 has been 
shown to sequester viral double stranded RNA so that it prevents activation of OAS and as a 
result its effector protein RNase L [267]. 
1.20 Influenza A and Apoptosis 
The NS1 protein also inhibits the activation of caspase 3 and 7. This is accomplished by 
interaction of the p85 subunit of PI3 kinase with NS1. The inhibition of apoptosis by NS1 
primarily through the antagonism of the production of type I interferons is necessary to allow 
sufficient time for the virus to transcribe all necessary viral proteins and to replicate its RNA 
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genome. However later in the virus life cycle apoptosis has been shown to be necessary for 
efficient virion production. Influenza A possesses apoptosis inducing properties [268]. The viral 
protein PB1-F2 interacts with two mitochondrial proteins Adenosine nucleotide translocase3 and 
voltage dependent anion channel 1. This interaction leads to a disruption in the outer 
mitochondrial membrane allowing for the release of proapoptotic mediators [268,269]. The viral 
infection of lung epithelial cells also results in the secretion of death ligands FasL and TRAIL 
which induces apoptosis through death receptors on the surface of lung epithelial cells.  
The importance of the apoptotic process for efficient influenza A replication has been 
demonstrated in the overexpression of anti-apoptotic protein bcl-2 in epithelial cells and 
infecting them with Influenza A. These cells produced significantly fewer virus particles which 
contained misglycosylation of the hemagglutinin membrane protein. A similar phenomenon is 
demonstrated when caspase activation in particular caspase 3 is blocked in vitro.  When caspase 
3 is inhibited or the nuclear export machinery is inhibited both cause viral RNPs to accumulate in 
the nucleus and a large decrease in the numbers of progeny virus being formed [268]. 
The immune system utilizes apoptosis to eliminate influenza A infected lung epithelial cells. 
This is accomplished by the death ligands FasL and TRAIL. FasL is produced primarily by 
lymphoid cells and neutrophils. TRAIL is expressed by a wide population of cells including 
immune cells and epithelial cells. It has been demonstrated that recruited macrophages 
expressing CCR2 induces apoptosis in lung epithelial cells by means of TRAIL however not 
only infected epithelial cells but cells expressing low levels of death receptor 5 also undergo 
apoptosis which contributes to lung damage induced by the immune system [268]. 
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Sepsis is characterized as an overwhelming pro-inflammatory systemic response to an infection. 
Invading pathogens will trigger a host defense response involving the excessive production of 
inflammatory mediators including cytokines (TNF-α, IL-1β, IFN-γ) from 
monocytes/macrophages and other cells. Consequently, these cytokines will amplify the host 
response by stimulating the release of downstream inflammatory mediators. Collectively, these 
mediators produce the pathophysiological abnormalities observed during sepsis and septic shock. 
The pathogenesis of sepsis is very complex and involves overlapping and redundant intracellular 
signalling pathways leading to the misregulation of processes including cell adhesion molecule 
regulation, iNOS induction and apoptosis. These processes are broadly regulated by STAT, IRF 
and NF-κB transcription factors.  
1.21 Thesis Objectives 
This first objective of this study was to investigate the cytokine production and cell death seen in 
lungs of individuals infected with pandemic H1N1 2009 influenza A. The second objective is to 
characterize the levels of these cytokines from the sera of H1N1 infected individuals and 
investigate the apoptotic inducing ability of these sera on cells in culture. The final objective is to 
characterize the pro-inflammatory mediators found in the sera from individuals with bacterial 
induced sepsis. 
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Chapter 2: Pandemic H1N1 influenza A 
2.1 Introduction 
In 2009 a novel influenza virus began to circulate through the global population. The 
components of this strain were identified as containing genetic segments from a swine triple 
reassortment strain, which contains avian and human influenza virus components, and genetic 
segments from Eurasian swine influenza A [270]. This strain was identified in 2 cases from 
California from people who did not have contact with pigs indicating this strain was able to 
spread from human to human. By June 2009 the W.H.O. declared a pandemic for this strain of 
influenza A. Like the seasonal strains of influenza A pandemic H1N1 2009 the most common 
clinical manifestations experienced were fever, headache, sore throat, chills and muscle aches 
[271]. Those most at risk of developing complications were people with pre-existing respiratory 
illnesses, heart conditions, pregnant women, obese people and diabetics. Similar to pandemic 
strains in the past severe and fatal cases of the flu were being experienced by a younger age 
group then from seasonal strains [271]. Since the first cases of pandemic influenza H1N1 (2009) 
were noted on the east coast of Canada on April 23, 2009, several thousand patients have been 
hospitalized with a significant subset requiring ICU care [272,273]. The largest initial outbreak 
of severe disease in Canada was seen during May and June in Manitoba where over 50 patients 
required ICU care over an 8 week period [274].  During this outbreak, seven adult deaths due to 
laboratory confirmed H1N1 occurred.  The lung pathology of 7 of these cases is reported along 
with assessments of cell death and cytokine production from these samples.  
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2.2 Methods 
2.2.1 Tissue samples and processing. All cases were confirmed by real-time reverse-
transcriptase–polymerase-chain reaction assay (PCR).  Complete autopsies were performed 
under the authority of the Provincial Medical Examiner, using standard precautions, and with the 
use of N95 masks.  Tissue sampled for histological evaluation was fixed in 10% formalin, with 
routine processing to hematoxylin and eosin stained slides.  Slides from four to six areas of the 
lung were examined in each case.  Fresh tissue was submitted for viral studies and 
microbiological cultures. Portions of lung were collected in 10% buffered formalin and 
processed in a routine manner. 
2.2.2 Tissue staining. For immunohistochemistry, paraffin embedded tissue sections were 
quenched for 10 minutes in aqueous 3% H2O2 then pretreated with proteinase K for 15 minutes.  
The primary antibody was a mouse monoclonal antibody specific for influenza A nucleoprotein 
(NP) (F26NP9, produced in-house) and was used at a 1:10,000 dilution for one hour.  They were 
then visualized using a horse radish peroxidase labeled polymer, Envision® + system (anti-
mouse) (Dako, CA, USA),  reacted with the chromogen diaminobenzidine (DAB). The sections 
were then counter stained with Gill’s hematoxylin. 
5μm formalin fixed paraffin embedded sections of lung tissue were used for cytokine staining. 
Primary mouse monoclonal antibodies for TNF-α, IL-1β and IFN-γ (clones 28401, 8516 and 
25718) were purchased from R&D systems. Tissues were sectioned on an American Optics 
Spencer 820 rotary microtome. Sections were floated in a 45˚C water bath mounted on 
Superfrost
®
 Excell™ microscope slides (Fisher Scientific) and air dried. Dried slides were 
placed in a 45˚C incubator overnight removed and stored at room temperature until use. 
61 
 
Slides were dewaxed in 2 changes of xylene 5 minutes each. Washed 2 times each in an alcohol 
series ranging from 100% to 70% 3 minutes each and finally washed in distilled water for 5 
minutes. 
Antigen unmasking was performed using Vector Labs high pH unmasking solution. Slides were 
immersed in the unmasking solution and autoclaved for 15 minutes at 121˚C. After 
depressurization slides were cooled to room temperature and then washed in distilled water for 5 
minutes. Slides were then transferred to a solution of tris buffered saline pH 7.4 (TBS) for 5 
minutes. Next slides were blocked with a solution containing 5% horse serum (Vector Labs), 1% 
bovine serum albumin fraction V (Fisher Scientific), 0.3% triton X 100 in TBS (TBST) for 1 
hour at room temperature. To block tissue binding of avidin and biotin slides were blocked in 
solutions of avidin and biotin (Vector Labs) for 30 minutes each. Next slides were incubated 
with primary antibody diluted 1 in 500 with 2% horse serum, 0.3% tritonX100 in TBS overnight 
at 4˚C. Slides were then rinsed with TBST and then washed in TBST for 5 minutes 3 times. 
Slides were then incubated with secondary antibody (Vector Universal Elite ABC Kit) diluted 1 
in 300 with same diluent as the primary antibody for 1 hour at room temperature. Slides were 
rinsed for 5 minutes 3 times in TBST. Slides were quenched of endogenous peroxidase activity 
by incubating in a solution containing 1% hydrogen peroxide, 0.5% sodium azide in TBS for 30 
minutes. The avidin biotin complex was formed by adding equal volume of each to tube (Vector 
Universal Elite ABC kit) and incubated for 30 minutes. After quenching the slides were washed 
3 times in TBST and then incubated with the avidin biotin complex 30 minutes at room 
temperature. Slides were rinsed with TBST 5 minutes 3 times. Slides were developed using 
ImmPact™ DAB Peroxidase Substrate (Vector Labs) according to manufacturer’s instructions 
for 10 minutes. Slides were then rinsed with water for 5 minutes and then counterstained with 
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Hematoxylin nuclear counter stain (Gill’s Formation) (Vector Labs). Finally slides were 
dehydrated in an alcohol series, clarified in 2 changes of xylene and mounted with Permount™ 
(Fisher Scientific). After curing slides were documented with a Ziess Axiovert 200M inverted 
microscope. 
2.2.3 TUNEL Assay. TUNEL assay was performed on 5µm sections of paraffin embedded 
tissues. The TUNEL assay was performed according to manufacture’s protocol (Trevigen, 
Gaithersburg MD) with the following modifications. The sections were permeabilized with a 
1:50 dilution of proteinase K in water and incubated for 20 min. at 37˚C. Manganese was used as 
the cation for the labeling reaction. The conjugate streptavidin HRP was incubated for 20 min. at 
37˚C and the substrate TACs blue was developed for 2.5 min. Sections were counterstained in 
nuclear fast red, mounted with Permount (Fisher Scientific) and coverslipped. The slides were 
documented on an Axiovert 200M inverted microscope (Ziess).  
2.3 Results  
The patients ranged in age from 17 to 55 years.  Five were of aboriginal origin, and two were 
Caucasian.  There were 6 females and one male.  All patients presented with a history of recent 
onset cough with fever and systemic symptoms of flu like illness, and were clinically suspected 
to have influenza.  Two deaths occurred late in the third trimester of pregnancy, both cases 
requiring delivery by urgent caesarean section resulting in one still birth, and one live birth with 
a surviving infant.  Only one of the deaths occurred in an individual with no known underlying 
medical condition. None of the individuals had received the H1N1 Influenza vaccine, with the 
exception of one (case 1), who received the vaccine four days prior to becoming symptomatic, 
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and died the following day. Table 2-1 summarizes the patient characteristics, time from 
presentation to death, and histopathology of the lungs at autopsy.    
At autopsy gross examination revealed the lungs to be diffusely congested, consolidated and 
variably hemorrhagic in all cases.  Correspondingly, the lungs were generally heavy, with 
weights ranging from 335 g to 1245 g (average 1027 g) for the right lung; and 330 g to 1340 g 
(average 1000 g) for the left lung (normal lung weight about 450 g).  In all cases, bilateral pleural 
effusion which was frequently blood tinged was present, with the exception of one case in which 
chest tubes were in place.    
The shortest duration between presentation and death occurred in cases 1 and 2, and in both 
cases the lungs demonstrated a similar microscopic picture.  The predominant finding was 
striking and widespread dilatation of pulmonary alveolar capillaries and marked congestion of 
pulmonary vasculature in general.  There was no evidence of capillaritis or histological alveolar 
wall damage.  There was moderate pulmonary edema in one case, and evidence of edema was 
present within lobular septae, but inconspicuous within alveolar spaces in the other.  Patchy 
interstitial lymphocytic infiltrates were present within the alveolated parenchyma but were 
generally inconspicuous. Mild peribronchiolar lymphocytic infiltrates were seen in case 1. Rare 
perivascular infiltrates with foci of subtle endothelialitis were seen in case 2. 
Table2-2 summarizes the staining for influenza A nucleoprotein and cytokines for these 7 cases. 
See appendix table A-1 and figures A-1 to A-3 for additional samples.  The viral protein was 
detected in both the nucleus and cytoplasm of infected cells (Figure 2-1). Cytokine staining was 
similar for all three targets TNF-α, IFN-γ and IL-1β. Weak staining was observed primarily in 
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the infiltrating leukocytes with no staining observed in the epithelial cells (Figure2-2, 2-3 and 2-
4). 
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Case Age 
(years) 
Sex Co-morbidities / 
Pertinent Medical 
History 
Days from onset 
of illness to 
death 
Primary Lung Findings at Autopsy 
1 35 F Down Syndrome 1 Marked pulmonary capillary and vascular congestion, 
alveolar hemorrhage 
2 46 
 
M None 4  Marked pulmonary capillary and vascular congestion, 
alveolar hemorrhage 
3 45 F Obesity, hypertension, 
asthma 
9 Marked pulmonary capillary and vascular congestion, 
alveolar hemorrhage, mild diffuse interstitial pneumonitis 
(lymphocytic alveolitis),  foci of early acute lung injury with 
occasional hyaline membranes 
Table 2-1 Demographic and pathological findings from pandemic H1N1 2009 cases 
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Demographic and pathological data from 7 fatal cases of pandemic H1N1 infections 
4 55 
 
F Obesity (BM1 47.4) 
Rheumatoid Arthritis, 
recent course of 
Prednisone 
11 Organizing diffuse alveolar damage, with striking type two 
pneumocyte hyperplasia, and occasional residual hyaline 
membranes and airspace fibrin 
5 17 
 
F Pregnant (third 
trimester) 
19 Pulmonary vascular congestion, mild interstitial 
pneumonitis, airspace macrophages, patchy type two 
pneumocyte hyperplasia and airspace fibrin deposition. 
6 24 
 
F Pregnant (third 
trimester) 
21 Organizing hemorrhagic diffuse alveolar damage 
7 32 
 
F Rheumatoid arthritis, 
Diabetes Mellitus, 
underlying lung fibrosis   
53 Organizing acute lung injury with extensive airspace 
fibroplasia, vascular congestion and patchy alveolar 
hemorrhage, mild patchy interstitial pneumonitis. 
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Table 2-2. Summary of immunohistochemical staining for H1N1 viral proteins and cytokines in lung tissue. 
Case No. IHC Score 
for virus 
Location of 
staining 
Cell types with positive staining for virus TNF-α IFN-γ IL-1β 
1 ++++ B/A Airway Epithelium, Type II pneumocytes, 
macrophages 
++ + Negative 
2 +++ B/A Type I and II pneumocytes + Negative Negative 
3 + B Airway Epithelium + Negative Negative 
4 + N/A Type II pneumocytes Negative Negative Negative 
5 + C/I Macrophages and Neutrophils ++ Negative + 
6 + C/I* Macrophages and Neutrophils ++ + + 
7 ++ B/A Type II pneumocytes and Macrophages ++ ++ + 
 
Immunohistochemistry staining for viral nucleoprotein and cytokines TNFα, IL-1β and IFN-γ were performed on 5μm sections of lung 
tissue from autopsy samples. Proteins were detected by diaminobenzidine and counterstained with hematoxylin. The level of staining 
is indicated by the symbol + weak staining, ++ strong staining and +++ for heavy staining. Location of staining for viral protein A= 
alveolar, I= interstitial, C= cytoplasmic, N= nuclear and B= both
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Figure 2-1 31 year old male with 1 day of severe respiratory symptoms with PCR confirmed 
H1N1 infection.  Section of lung with immunohistochemical staining for influenza A nucleoprotein using mouse 
monoclonal antibody.  Note heavy staining of antigen in nucleus and cytoplasm of Type II pneumocytes. 
Bar = 20 µm  
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Figure 2-2. Immunohistochemical staining for TNF-α of autopsy lung tissue from H1N1 
infections. 5μm sections of lung tissue where stained for TNF-α using the chromogen diaminobenzedine (DAB) 
(brown) and counterstained with hematoxylin (blue).  
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Figure 2-3. Immunohistochemical staining for IFN-γ of autopsy lung tissue from H1N1 
infections.5μm sections of lung tissue where stained for IFN-γ using the chromogen diaminobenzedine (DAB) 
(brown) and counterstained with hematoxylin (blue).  
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Figure 2-4. Immunohistochemical staining for IL-1β of autopsy lung tissue from H1N1 
infections.5μm sections of lung tissue where stained for IL-1β using the chromogen diaminobenzedine (DAB) 
(brown) and counterstained with hematoxylin (blue).  
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TUNEL positive tissues demonstrated extensive cell death localized to the interstitium of 
consolidated areas of tissue. The vast majority of TUNEL positive cells were mononucleated 
leukocytes. Other cell types positive for TUNEL included fibroblasts and to lesser extent 
endothelial cells. The alveolar epithelial cells were primarily TUNEL negative in the vast 
majority of the sections (Figure 2-5)
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Figure 2-5. TUNEL assay on autopsy lung tissue from H1N1 infections. TUNEL assay was 
performed on 5μm sections of lung tissue from adults who succumb to pandemic H1N1 2009 infections. A-G 
corresponds to cases 1-7. Blue nuclei indicate TUNEL positive cells. Cells were counterstained with Nuclear Fast 
Red.    
 
No histological evidence of secondary bacterial infection was seen in any of the cases, and no 
pathogenic bacteria were cultured from the autopsy tissue.  Viral cultures performed on lung 
tissue obtained at the time of autopsy were positive in case 1, and negative in all other cases. 
There was no evidence of pulmonary embolism in any of the cases. 
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2.4 Discussion  
This autopsy study reflects fatalities due to pandemic influenza A H1N1 (2009) in Manitoba, 
Canada during the spring and fall of 2009.  Several studies have already noted remarkable 
aspects of this epidemic in Canada [273].  The age of those who become severely ill and those 
who die is significantly younger than seen in fatalities due to seasonal influenza.  There is 
preponderance of women (6/7 deaths) and an association with the presence of underlying disease 
(4/5 non pregnant cases), and pregnancy (2/7, both in 3rd trimester), factors previously noted in 
an analysis of ICU-requiring pH1N1 cases in Canada [273].  The presence of two women in the 
3rd trimester of pregnancy is concordant with data suggesting that pregnant women may be at 
increased risk for severe complications H1N1 influenza [273,275].  That 5 of 7 deaths occurred 
among individuals who were of Native Canadian ethnicity, appears to reflect the 
disproportionate fraction of patients with that background in the Manitoba cohort of severely ill 
individuals rather than a specific vulnerability of that population to poor outcomes. However, 
further research will clearly be required to determine whether aboriginals may have an increased 
predisposition to either acquiring infection or developing severe manifestations of infection.   
Cases 1 and 2 are of particular interest, since they represent fulminant disease which was rapidly 
fatal within one to several days of onset, and provide an insight into the earliest pathology in the 
lung.  Data on such early deaths is scant.  The main finding was marked capillary vascular 
congestion and alveolar hemorrhage.  Frothy bloody fluid was noted clinically antemortem and 
by clinicians during initial intubation in case 2, and was evident within the trachea and bronchi at 
the time of autopsy in both cases. Clinical descriptions of severe influenza pneumonia from the 
current epidemic as well fatal cases from the 1918 pandemic also described frothy pink or 
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bloody sputum [276,277].  The presence of vascular congestion and perivascular infiltrates 
suggests that a perturbation in the pulmonary vasculature at the level of the capillary may play a 
significant role early in disease.   
The pathology of the lung (with the exception of cases 1 and 2) reflects a non-specific reaction 
pattern of alveolar injury (“acute lung injury”) and repair (“organization”).  While these finding 
are consistent with primary viral pneumonia, there are no specific pathological markers for viral 
etiology (such as viral inclusions) based upon tissue examination.  The diagnosis requires 
correlation with clinical case definition and confirmatory laboratory studies such as viral culture 
or identification of viral antigens/nucleic acids.  The spectrum of findings in the lungs in these 
cases is qualitatively similar to the pathology described in the H1N1 influenza pandemic of 
1918, the smaller pandemics in 1957 and 1968 and in seasonal influenza [276,278-281].   
The data also suggest an evolution of the dominant pulmonary pathology with increasing 
durations since illness onset.  The cases where deaths occurred early demonstrated marked 
capillary and vascular congestion with alveolar hemorrhage.  Tissues from deaths occurring in 
the 2nd week tended to demonstrate increasing frequency of hyaline membranes and diffuse 
alveolar damage with pneumocyte hyperplasia. Late deaths demonstrated evidence of organizing 
injury.  In the one patient who died after 53 days, extensive airspace fibroplasia was seen.  In 
short, specific findings will depend upon how quickly death has supervened, along the spectrum 
of initial infection and tissue damage.  With the availability of intensive care and longer survival 
of severe lung injury, various degrees of tissue repair reaction are observed.   
Bacterial pneumonia is well recognized to supervene in many cases of viral pneumonitis and to 
be associated with rapid deterioration and death.  Many, if not most of the deaths, during the 
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1918 pandemic were ascribed to secondary bacterial infection and similar evidence of pulmonary 
superinfection has been described in more recent pandemics including the current one [281-285].  
Interestingly, none of the cases examined had any evidence of secondary bacterial pneumonia.   
Classic studies of severe influenza viral pneumonia have demonstrated consistent findings of 
early injury including interstitial edema with inflammatory infiltrates, capillary and small vessel 
thrombosis, hyaline membrane formation, variable acute intra-alveolar edema/hemorrhage,  
fibrin deposition, diffuse alveolar damage and frequently necrotizing tracheitis/bronchitis and 
bronchiolitis [276,286].  Later stages typically have shown organization of alveolar injury, with 
fibrosis, epithelial regeneration and squamous metaplasia.  Findings described in previous 
autopsy studies include tracheitis and necrotizing bronchiolitis, which were not identified in the 
current cases. Bronchiolitis was not a striking feature in any of the cases, although mild 
peribronchial and peribronchiolar infiltrates were identified.   Thrombosis is mentioned in 
previous autopsy studies [276,286].  Focal thrombosis was identified in a few cases, however 
since in-situ thrombi within pulmonary parenchymal arterioles are an expected finding in acute 
lung injury of any cause, this cannot be assumed to be a specific finding in influenza pneumonia. 
One report of severe pH1N1 pneumonia suggested a high frequency of pulmonary emboli [287].  
No pulmonary emboli were seen in this autopsy series.   
In all of the cases studied, some detachment of bronchial epithelium was seen. In the opinion of 
the authors this is most likely an artefact of autopsy material.  Since surgical biopsy is generally 
not indicated in clinical cases of influenza, descriptions of findings from specimens other than 
autopsy tissue are very limited.  Yelandi and Colby [288] described six open lung biopsies in 
patients subsequently diagnosed with influenza pneumonia. The one case was ultimately fatal 
demonstrated necrotizing bronchiolitis and diffuse alveolar damage with hyaline membranes.   
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Of the remaining patients (four who recovered and one lost to follow up), three demonstrated 
milder organizing acute lung injury; and two had a bronchiolitis-obliterans organizing 
pneumonia (BOOP)/cryptogenic organizing pneumonia (COP).   Desquamation of bronchial 
mucosa was not noted.  
TUNEL assay demonstrated interstitial leukocyte cell death. Monocytes and macrophages have 
been shown to induce apoptosis in influenza infected lymphocytes in a Fas dependent manner 
[288]. In addition influenza infected neutrophils also undergo apoptosis in a Fas dependent 
manner [289]. The expression of 3 pro-inflammatory cytokines was identified in the lung tissue 
from H1N1 infected adults. These cytokines play important roles in antiviral response and 
inflammation. TNF-α has been shown to be an important cytokine induced during influenza A 
infections [290] possessing antiviral activities. In addition this cytokine has been shown to prime 
lung epithelial cells to increase the production of chemokines necessary for the recruitment of 
leukocytes to the lung [291]. TNF-α also upregulates antiviral components of the TLR and RIG-I 
pathways both of which play a major role in the antiviral response to influenza A infections 
[292]. TNF-α can be membrane bound or cleaved to form a soluble form. The soluble form of 
TNF-α has been demonstrated to be necessary for coordinating an effective immune response 
against influenza A and lack of this form of TNFα resulted in a dysregulated immune response 
leading to worsening lung injury [293].  
In conclusion, the lung morphology in seven fatal cases of H1N1 pneumonia has been described. 
The pathological findings are non-specific but consistent with influenza reflecting acute lung 
injury and repair and are qualitatively similar to previous descriptions of autopsy tissues during 
previous pandemics and with seasonal influenza.  A progressive sequence of histopathological 
features has been classically observed and is reproduced in this series. That sequence includes 
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early vascular congestion and alveolar hemorrhage followed by the formation of hyaline 
membrane and diffuse alveolar damage with pneumocyte hyperplasia. In later stages, evidence of 
organization of injury and fibrosis is seen in fatal cases.  
83 
 
Chapter 3: H1N1 Septic Sera Characterization and Cellular Signalling in 
Fibroblasts 
3.1 Introduction 
Viral pneumonia induced by pandemic H1N1 infection is a major complication from this 
infection. It has the potential to lead to the more serious ARDS and death. Autopsy studies of 
pandemic H1N1 infected adults shows significant damage to the lungs. This damage is believed 
to result from both the replicating virus and the host immune response to the infection. Massive 
infiltrating leukocytes, dysfunction of the blood air barrier from increased permeability of the 
endothelium and loss of alveolar epithelial cells implicate cell death as a major contributor to 
lung dysfunction induced by pandemic H1N1 pneumonia. The host immune system utilizes 
apoptosis to clear infected cells and proteins from influenza A have been shown to modulate 
apoptosis as well. The downstream transcription factor targets from the various induces of 
apoptosis is an important point of cell signalling. STATs have been shown to play an important 
role not only in antiviral defense but also in broadly regulating apoptosis. 
The STAT family is comprised of seven members: STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b and STAT6. STAT family members are characterized by a highly conserved STAT 
homology (SH2) domain that facilitates dimerization via interactions between phosphotyrosine 
residues. Differences in the SH2 domain determine which of the STAT proteins will be recruited 
to a particular receptor. Each protein also contains a highly conserved tyrosine residue in the C-
terminal region that is phosphorylated upon activation. The DNA binding domain is located 
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centrally and there is typically an oligomerization domain in the C-terminal region. STATs 
reside in the cytoplasm in a hypophosphorylated (inactive) form until phosphorylated by a Janus 
Activation Kinase (JAK). JAKs are receptor associated tyrosine kinases constitutively bound to 
cytokine and hematopoietin receptors. There are four members of the JAK family: JAK1, JAK2, 
JAK3 and TYK2. JAK1, JAK2 and TYK2 are ubiquitiously expressed but JAK3 has limited 
distribution.  
The JAK/STAT pathway is essential in the biological response to cytokines. Binding of a 
cytokine ligand to its cognate receptor triggers dimerization bringing two JAK proteins into 
immediate proximity. Trans-auto-phosphorylation of the JAK proteins leads to activation and 
phosphorylation of the associated receptors. This induces a conformational change in the 
receptors that create a high-affinity docking site for STAT proteins. STAT proteins are recruited 
and phosphorylated by the JAKs after which they have a higher affinity for each other causing 
dimerization and dissociation from the receptor complex. No further modification is necessary 
before the STAT dimer is able to translocate to the nucleus and mediate transcription. 
Mutant cell lines were created from HT1080 cells that lack specific Jak and STAT family 
members.  2fTGH cells showed no defect in IFN signalling, U1A cells lack Tyk2, U2A cells lack 
p48, U3A cells lack STAT1, U4A cells lack Jak1, U5A cells lack IFN-α receptor, U6A cells lack 
STAT2 and 2A cells lack Jak2.    We have performed H1N1 septic sera experiments in HT1080, 
2fTGH, U3A and U3AR cells.  These experiments showed that STAT1 is required to mediate 
H1N1 septic sera induced apoptosis. 
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3.2 Methods 
3.2.1 Human Sera: Serum was derived from 8 patients who were in sepsis as defined by 
modified ACCP/SCCM Consensus Conference criteria induced by H1N1 influenza A infection. 
All pandemic H1N1 infections were PCR confirmed. Patients were required to have all (rather 
than a minimum of two) of the following four criteria for systemic inflammatory response 
syndrome 1) a body temperature greater than 38
o
C or less than 36
o
C; 2) a heart rate greater than 
90 beats per minute; 3) tachypnea, manifested by a respiratory rate greater than 20 breaths per 
minute or hyperventilation, as indicated by a PaCO2 of less than 32 mm Hg; 4) an alteration in 
the white blood cell count (i.e. WBC greater than 12,000/ mm
3
, less than 4,000/mm
3
, or the 
presence of more than 10% immature neutrophils). Serum samples were obtained within 48 
hours of admission.  Human septic serum was obtained after informed consent under an 
approved Institutional Review Board (University of Manitoba) protocol.  Subjects contributing 
HSS for this study were not known to have pre-existing structural heart disease. 10 cc of blood 
was drawn from the patient and centrifuged for 10 min at 1700xg.  The supernatant representing 
the serum was aliquoted and stored at -70
o
C. Normal human serum was obtained from 
commercial sources (Sigma Laboratories). 
3.2.2 ELISA: Human septic and normal serum concentrations of TNF-α, IL-1β and IFN-γ were 
determined by ELISA.  The assay is based on an ELISA with Streptavidin conjugated to HRP 
and TMB was the substrate used.  For the detailed protocol, refer to the DuoSet ELISA 
Development System on the website www.RnDSystems.com or in the following product 
manuals: Human TNF-α/TNFSF1A, Catalog Number: DY210; Human IL-1β/IL-1F2, Catalog 
Number: DY201; and Human IFN-γ, Catalog Number: DY285.  The following modifications 
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were made to the ELISA protocol. Four washes were performed instead of three in order to 
reduce the background.  Furthermore, the reagent diluents were optimized for the quantification 
of each cytokine.  The diluents consisted of 10% FCS with PBS, 2% FCS with PBS and 0.5% 
FCS with PBS for TNF-α, IL-1β and IFN-γ, respectively. 
3.2.4 Trypan Blue Exclusion Assay:  HT1080, 2fTGH, U3A, U3A R cells (5 x 10
4
 cells/96 well 
plate) were treated with 5% uninfected sera, 5% H1N1 infected sera in DMEM as indicated.  
After 12 h, the cells were trypsinized and viable cells counted using trypan blue exclusion assay.  
The caspase 3, -6, -7, -8, -10 inhibitor Ac-DEVD-CHO; (Calbiochem; caspase inhibitors were 
prepared in DMSO at a stock concentration of 10 mM and used at a concentration of 10 μM in 
tissue culture) was prepared in ethanol at a stock concentration of 50 mg/mL and used at a 
concentration of 100μM in tissue culture were added individually at the same time as the 5% 
normal or 5% H1N1 infected serum. 
3.2.5 TUNEL Assay: TUNEL assay was performed on HT1080, 2fTGH, U3A and U3AR cells 
using the R&D systems/Trevigen HT TiterTACS (Trevingen Apoptotic Cell System) 
colourimetric assay.  Refer to catalogue number 4822-96-K. Cells seeded at 5X10
4
 cells/well 
were treated with either 5% uninfected serum or 5% H1N1 infected serum for 12 hours. Cells 
were fixed in plate with 3.7% buffered formaldehyde (in PBS) for 10 minutes, washed in PBS 
fixed with methanol for 20 minutes washed in PBS and then labelled according to 
manufacturer’s protocol. The reaction was read on a Fluostar Optima plate reader (BMG 
Labtech). 
3.2.6 Caspase 3 Assay:  Caspase 3 assay was performed on HT1080, 2fTGH, U3A and U3AR 
cells using the Cell Signalling Caspase 3 Activity Assay Kit (#5723). Cells were seeded in a 96 
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well plate at 5X10
4
 cells/well. The cells were treated with either 5% uninfected serum or 5% 
H1N1 infected serum for 12 hours. Next the cells were lysed on plate using supplied lysis buffer 
and assayed according to manufacturer’s protocol. Fluorescence was read on a Fluostar Optima 
plate reader (BMG Labtech). 
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3.3 Results 
Sera from H1N1 infected adults has the ability to induce cell death in fibroblast cells HT1080, 
2fTGH and U3AR1 cells compared to sera from uninfected adults (Figure 3-1 A,B,D,E,F,H). 
U3A cells show resistance to H1N1 infected sera induced cell death (Figure 3-1G). 
HT1080  
A 
U3A  C 
U3A R1 D 
2fTGH  B 
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Figure 3-1. Light micrographs of fibroblasts treated with uninfected and H1N1 infected sera. 
Fibroblast cells were seeded in a 96 well plate at a density of 5X10
4
 cells per well. Cells were treated with either 5% 
uninfected sera or 5% H1N1 infected sera for 18 hours. A-D fibroblasts treated with uninfected sera, E-H cells 
treated with H1N1 sera. 
 
U3A  
HT1080  
E 
2fTGH  
F 
G U3A R1 H U3A  
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H1N1 sera had elevated levels of the cytokines TNF-α, IFN-γ and IL-1β (Table 3-1). The H1N1 
sera had an average of 113 pg/mL, 49 pg/mL and 26 pg/mL for TNF-α, IFN-γ and IL-1β 
respectively while the sera from uninfected adults had undetectable levels of these cytokines. 
 
Table 3-1. Serum concentration of cytokines from fatal cases of pandemic H1N1 infections. 
Sample ID TNF-α (pg/mL) IFN-γ (pg/mL) IL-1β (pg/mL) 
H1 21 13 15 
H2 18 26 16 
H3 65 33 48 
H4 72 17 34 
H5 58 22 71 
H6 229 47 63 
H7 87 14 54 
H8 351 39 92 
N1 0 0 0 
N2 0 0 0 
N3 0 0 0 
N4 0 0 0 
N5 0 0 0 
N6 0 0 0 
N7 0 0 0 
N8 0 0 0 
 
Serum concentrations for TNF-α, IFN-γ and IL-1β were determined for 8 adults infected with pandemic H1N1 
influenza A (H), and 8 uninfected adults (N) using sandwich ELISA. Values are averages from duplicate readings. 0 
indicates below detection limit. 
 
H1N1 sera induced apoptosis in HT1080 and 2fTGH cells as determined by trypan blue 23% for 
both cell lines (Figure 3-2). TUNEL assays indicates H1N1 infected sera induced DNA breaks in 
HT1080 and 2fTGH cells to a greater degree then uninfected sera (Figure 3-3).  U3A cells were 
resistant to H1N1 induced apoptosis (Figures 3-2, 3-3) decreasing the levels of dead cells to 
levels slightly greater then the uninfected sera (see appendix for individual sera results).  H1N1 
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sera induced apoptosis in U3A rescues cells (U3AR) to levels of the parental lines HT1080 and 
2fTGH cell lines which implicates transcription factor STAT1 in mediating H1N1 sera induced 
apoptosis. 
 
Figure 3-2. Trypan blue staining of fibroblast cell lines treated with sera from H1N1 infected and 
uninfected sera. Fibroblast cell lines HT1080, 2fTGH, U3A and U3AR were seeded in 96 well plates at a density 
of 5X10
4
 per well and treated with either 5% H1N1 infected sera or 5% uninfected sera for 12 hours before staining. 
Values plotted are avereages of duplicate counts expressed as percent dead cells. Error bars represent standard error 
of the mean. * p<0.05 t-test for uninfected vs H1N1 infected sera by cell type 
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Figure 3-3. TUNEL assay of fibroblast cell lines treated with sera from H1N1 infected and 
uninfected sera. Fibroblast cell lines HT1080, 2fTGH, U3A and U3AR were seeded in 96 well plates at a density 
of 5X10
4
 per well and treated with either 5% H1N1 infected sera or 5% uninfected sera for 12 hours before staining. 
Values plotted are avereages of duplicate counts expressed as percent dead cells. Error bars represent standard error 
of the mean. * p<0.05 t-test for uninfected vs H1N1 infected sera by cell type 
 
H1N1 sera treatment of HT1080 and 2fTGH cells led to the activation of caspase 3 as 
determined by caspase 3 colourimetric assay (Figure.3-3) compared to uninfected sera.  Caspase 
3 activation was greatly reduced to levels slightly greater then uninfected sera in U3A cells 
treated with H1N1 sera as compared to parental lines HT1080 and 2fTGH (see appendix for 
individual serum results). Caspase 3 activation was restored in U3AR cells to levels comparable 
to the parental cell lines implicating STAT1 in mediating caspase 3 activation.   
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Figure 3-4. Caspase 3 activity assay of fibroblast cell lines treated with sera from H1N1 infected 
and uninfected sera. Fibroblast cell lines HT1080, 2fTGH, U3A and U3AR were seeded in 96 well plates at a 
density of 5X10
4
 per well and treated with either 5% H1N1 infected sera or 5% uninfected sera for 12 hours before 
assaying for caspase 3 activity. Values plotted are avereages of duplicate counts expressed as relative fluorescent 
units. Error bars represent standard error of the mean. * p<0.05 t-test for uninfected vs H1N1 infected sera by cell 
type 
 
Treatment of HT1080, 2fTGH and U3AR cells with the caspase 3 inhibitor Ac-DEVD-CHO 
reduced H1N1 sera induced apoptosis in these cell lines (Figure 3-5) (see appendix for individual 
sera results). 
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Figure 3-5. Trypan blue staining of fibroblast cell lines treated with caspase inhibitor and sera 
from H1N1 infected and uninfected sera. Fibroblast cell lines HT1080, 2fTGH, U3A and U3AR were 
seeded in 96 well plates at a density of 5X10
4
 per well and treated with caspase 3 inhibitor Ac-DEVD-CHO and 
either 5% H1N1 infected sera or 5% uninfected sera for 12 hours before staining. Values plotted are avereages of 
duplicate counts expressed as percent dead cells. Error bars represent standard error of the mean. * p<0.05 t-test for 
uninfected vs H1N1 infected sera by cell type 
 
* * 
* 
* 
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3.4 Discussion 
In this study it has been shown that the sera from pandemic H1N1 infected adults contain high 
levels of the cytokines TNF-α, IFN-γ and IL-1β (Table 3-1). These levels are higher than those 
found in sera of adults with bacterial induced sepsis [294].  Pandemic strains of influenza A have 
the potential to illicit stronger inflammation and cytokine production since the population 
generally has little or no immune exposure to those strains. This potentiates a higher probability 
of inducing a hyper inflammatory state in those infected. In addition the virulence of the strain of 
influenza A and the viral load induces a stronger inflammatory response. Influenza A has 
evolved mechanism to antagonize the antiviral response yet allows for the continued production 
of inflammatory cytokines. This combination potentiates the developed of influenza A induced 
sepsis. 
The sera from H1N1 infected individuals demonstrated the ability to induce apoptosis in treated 
fibroblast cells. A recent study in mice demonstrated that injury to the cornea from lasers 
induced the expression of TNF-α, IL-1β and IFN-γ. They attributed these cytokines to the 
induction of apoptosis of the endothelium of the cornea demonstrating the apoptotic potential of 
these inflammatory cytokines [295]. In addition to the apoptotic inducing signalling by TNF-α 
other members of the TNF family have been shown to be important mediators of viral clearance. 
Fas ligand and TRAIL are both mediators of apoptosis utilized by the immune system to kill 
influenza A infected cells. The presence of other inflammatory cytokines would also have a 
contribution to the apoptosis inducing ability of the H1N1 infected sera as it has been shown that 
cytokines can work synergistically and induce the activation of similar transcription factors 
which regulate the inflammatory and apoptotic processes.  
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The observation that U3A cells are generally resistant to the apoptotic effects of H1N1 infected 
sera implies a role for STAT1 in mediating the apoptotic signalling. It has been shown that IFN-γ 
induced activation of STAT1 mediates apoptosis in A431 cells [296]. They also demonstrated 
that this induction of apoptosis requires STAT1 induced expression of caspase1. The 
requirement for STAT1 in mediating TNF-α induced apoptosis has been demonstrated [297]. 
The inflammatory effects of IFN-γ can be amplified by the presence of other mediators in the 
sera. Gao et al demonstrated the synergistic effect of IL-17 on IFN-γ induced production of 
iNOS in macrophages [298]. This effect was mediated by STAT1 further implicating the 
importance of STAT1 not only in mediating apoptosis but in mediating inflammatory processes. 
3.5 Conclusion 
Sera from pandemic H1N1 infected adults contain inflammatory mediators. In addition the sera 
possess the ability to induce apoptosis in fibroblast cells. This process is mediated in part by 
STAT1 making this a potential target in understanding the cellular injury that occurs during 
influenza infections. 
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Chapter 4: Characterization of Factors in Human Septic Sera that 
Mediate Cellular Dysfunction 
4.1 Introduction 
Sepsis and septic shock are the leading cause of morbidity and mortality in noncoronary 
intensive care units worldwide [299-301].  Annually, sepsis develops in approximately 800,000 
people with a mortality rate that approaches 50% [299-301] and the yearly frequency of sepsis 
incidence has been increasing by 9% per year [1,301].  During bacterial sepsis the release of 
bacterial endotoxins and exotoxins induce the cellular production and release of pro-
inflammatory cytokines which include tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β 
and interferon (IFN)-γ.  This is followed by production of chemokines, which are small 
chemotactic cytokines, such as growth-related oncogene (GRO), monocyte chemo-attractant 
protein (MCP)-1, and IL-8 [302,303].  At a later stage, anti-inflammatory cytokines such as IL-
10 and IL-5 are produced. The complex expression of cytokines and chemokines mediates the 
process of inflammation [303].  The deregulation of the production of pro-inflammatory, anti-
inflammatory or chemokines mediators can lead to damage to the host.   
Previous studies, which have targeted individual cytokines and chemokines during sepsis, have 
not been successful to date [304,305].  The use of activated protein C (APC) is the only approved 
sepsis therapy which modulates the host cytokine responses. Using antibody blot array 
technologies we can specifically identify sera factor profile during sepsis and septic shock.  In 
addition, by assessing the key cytokine, chemokine and growth factor expression levels, it will 
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be possible to initiate therapies that modulate the host response at the most advantageous time 
during the course of the disease.  
 Using antibody blot arrays, we have determined the differential cytokine, chemokine and growth 
factor expression profile comparing four normal sera to four septic sera.  We observed that the 
levels of key cytokines, chemokines and growth factors were differentially expressed in the sera 
of septic patients as compared to the sera of healthy individuals. The pro-inflammatory cytokines 
including, TNF-α, IL-1β, IFN-γ, IL-7 and IL-15, were increased in the sera of septic patients 
when compared to the sera from healthy volunteers.  In addition the anti-inflammatory cytokines 
IL-5, IL-10, and IL-13; the chemokines MCP-1, MCP-2, IL-8, GRO, GRO-α, TARC, SDF-1, 
MIG and MIP-1δ; and other factors such as leptin, angiogenin, EGF and PDGF-BB showed 
differential expression levels in the sera of septic patients when compared to the sera of healthy 
individuals.  These factors were also differentially regulated in the four individual septic sera.  
TNF-α was the only factor that showed elevated levels in all septic sera. Using antibody blot 
array technologies, key factors in septic sera will be identified and targeted for therapeutic 
interventions.  
4.2 Methods 
4.2.1 Study Patients from whom HSS was obtained.  Serum was derived from 4 patients who 
were in acute phase of septic shock as defined by modified ACCP/SCCM Consensus Conference 
criteria.  Patients were required to have all (rather than a minimum of two) of the following four 
criteria for systemic inflammatory response syndrome 1) a body temperature greater than 38
o
C 
or less than 36
o
C; 2) a heart rate greater than 90 beats per minute; 3) tachypnea, manifested by a 
respiratory rate greater than 20 breaths per minute or hyperventilation, as indicated by a PaCO2 
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of less than 32 mm Hg; 4) an alteration in the white blood cell count (i.e. WBC greater than 
12,000/ mm
3
, less than 4,000/mm
3
, or the presence of more than 10% immature neutrophils).  In 
addition, all patients whose serum samples were utilized exhibited positive blood cultures with a 
defined focus of infection (e.g. peritonitis or pneumonia) and required substantial pressor therapy 
(>0.5 ug/kg/min norepinephrine) to maintain mean arterial pressure > 65 mm Hg. Serum samples 
were obtained within 24 hours of presentation with septic shock.  Human septic serum was 
obtained after informed consent under an approved Institutional Review Board (Rush 
University)-approved protocol.  Subjects contributing HSS for this study were not known to have 
pre-existing structural heart disease. 10 cc of blood was drawn from the patient and centrifuged 
for 10 min at 1700xg.  The supernatant representing the serum was aliquoted and stored at -70
o
C.  
Before use in experiments the serum was heat inactivated at 56
o
C for 45 min. Cytokine profiles 
of serum donors with septic shock is shown in Table 4-1. Normal human serum was obtained 
from laboratory personnel and commercial sources (Sigma Laboratories). 
4.2.2 Reagents.  Bradford dye reagent was and Bovine serum albumin (BSA) standards where 
purchased from BioRad (Mississauga, Canada).  TNF-α, IL-1β and IFN-γ were analyzed by 
commercial Enzyme-Linked Immunosorbent Assay (ELISA) kits were purchased from R&D 
Systems (Minniapolis, United States). Tetramethylbenzidine (TMB) was purchased from Pierce 
(Rockford, United States) and Streptavidin conjugated to horseradish peroxidase (HRP) from 
R&D Systems (Minniapolis, United States).  Fetal calf serum (FCS) was purchased from Sigma 
(Oakville, Canada) and the phosphate buffer saline (PBS) from Invitrogen (Burlington, Canada).  
The Human cytokine antibody array III kit was purchased from RayBiotech, Inc (Norcross, 
United States). 
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4.2.3 Bradford assay.  Human septic and normal sera total protein quantification was performed 
using the Bradford assay.  A standard curve was established using BSA with a concentration 
range from 0.2 µg/ml to 1.4 µg/ml.  Absorbance at a wavelength of 595 nm was read.  The 
absorbance of the sera were plotted on a standard curve to obtain the total protein concentration 
for each sample. 
4.2.4 Sandwich ELISA assays.  Human septic and normal serum concentrations of TNF-α, IL-1β 
and IFN-γ were determined by ELISA.  The assay is based on an ELISA with Streptavidin 
conjugated to HRP and TMB was the substrate used.  For the detailed protocol, refer to the 
DuoSet ELISA Development System on the website www.RnDSystems.com or in the following 
product manuals: Human TNF-α/TNFSF1A, Catalog Number: DY210; Human IL-1β/IL-1F2, 
Catalog Number: DY201; and Human IFN-γ, Catalog Number: DY285.  The following 
modifications were made to the ELISA protocol. Four washes were performed instead of three in 
order to reduce the background.  Furthermore, the reagent diluents were optimized for the 
quantification of each cytokine.  The diluents consisted of 10% FCS with PBS, 2% FCS with 
PBS and 0.5% FCS with PBS for TNF-α, IL-1β and IFN-γ, respectively. 
4.2.5 Human cytokine antibody array.  The human cytokine antibody array protocol was 
followed.  The detailed protocol can be found in RayBio® Human Cytokine Antibody Array 
Protocol, © 2004 RayBiotech Inc. or at http://www.raybiotech.com/manual/human_manual.pdf.  
Human septic and normal serum with 10 mg total protein was used to hybridize each membrane.  
Detection of signals on the membranes was performed using chemiluminescence and captured 
using BioRad ChemiDoc XRS imaging system. 
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4.2.6 Statistics.  For the blot arrays, the background, which was measured as the averaged 
negative controls, was subtracted from the intensity of every spot on the array.  In addition, the 
intensities were normalized to the positive controls for every blot.  A one-way analysis of 
variance (ANOVA) was performed for the statistical comparison, followed by Tukey’s test when 
suitable.  A level of p < 0.05 was considered to be significant. 
4.3 Results 
4.3.1 ELISA protein quantification. The levels of TNF-α, IL-1β and IFN-γ in the serum of the 
four septic patients and in the serum of healthy individuals were quantified using the Enzyme-
Linked Immunosorbant Assay (ELISA) kit from R&D Systems.  Patient SE was a female of 81 
years old that had Staphylococcus aureus as the infecting organism during sepsis.  Patient SE 
succumbed to the disease.  The levels of TNF-α, IL-1β and IFN-γ for this patient are 43.9 pg/ml, 
6.1 pg/ml and 22.8 pg/ml respectively (Table 4-1). Patient SF a male of 73 years, with the 
infecting organism Haemophilus influenzae survived from sepsis.  This patient had levels of 
TNF-α, IL-1β and IFN-γ of 13.4 pg/ml, 3.6 pg/ml and 6.8 pg/ml respectively.  Patient SG was 
infected with Escherichia coli.  This patient, a male of 68 years old also survived sepsis and the 
levels of cytokines measured from the serum of this patient were 19.0 pg/ml, 7.7 pg/ml and 10.3 
pg/ml for TNF-α, IL-1β and IFN-γ respectively.  The fourth serum SH was from a male of 54 
years of age with Staphylococcus pneumonia as the initial infecting organism for sepsis.  This 
patient also survived sepsis and had levels of 39.0 pg/ml, 1.8 pg/ml and 6.0 pg/ml for TNF-α, IL-
1β and IFN-γ in his serum.  Normal sera from healthy lab volunteers did not have measurable 
levels of TNF-α, IL-1β and IFN-γ. 
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Table 4-1: Demongraphic and Enzyme-linked Immunosorbant Assay Data 
 
Patient Gender Age Infecting organism Outcome TNF-α 
(pg/mL) 
IL-1β 
(pg/mL) 
IFN-γ 
(pg/mL) 
SE Female 81 
 
Staphylococcus 
aureus 
 
Died 43.9 6.1 22.9 
SF Male 73 Heamophilus 
influenzae 
Survived 13.4 3.6 6.8 
SG Male 68  Escherichia coli Survived 19.0 7.7 10.3 
SH Male 54 Streptococcus 
pneumoniae 
Survived 39.0 1.8 6.0 
Normal Healthy 
individual 
   --- --- --- 
Categorization of sepsis using physiological parameters of four septic patients (SE, SF, SG, and SH), and cytokine 
levels, measured with an Enzyme-Linked Immunosorbant Assay (ELISA) using the sera from the four septic 
patients.  The cytokine levels in the sera of four healthy volunteers were also measured (all normal serums 
quantified had non-detectable levels of cytokines). 
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4.3.2 Cytokine, chemokine and growth factor blot array.  The cytokine, chemokine and growth 
factor profile of the sera of septic patient SE, SF, SG and SH and the healthy individuals NA, 
NB, NC and ND was performed using RayBiotech cytokine blots (Figure 4-1A and B).  We 
performed an internal comparison of the cytokines between each healthy individual.   There was 
no statistical differences between the cytokine levels from one serum of healthy individuals to 
another, therefore the data was averaged and used to compare the relative cytokine level from the 
serum of the four septic patients.  Significant differences in the levels of many cytokines were 
observed in the serum of septic patients.  TNF-α showed the greatest relative increase to normal 
serums and in addition, was the only cytokine that was commonly up-regulated in all septic 
serums (Table 4-2).  
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Figure 4-1A Cytokine Blot Array Map 
  a b c d e f g h i j k l 
1 Pos Pos Neg Neg ENA-78 GCSF GM-CSF GRO GRO-α l-309 IL-1α IL-1β 
2 Pos Pos Neg Neg ENA-78 GCSF GM-CSF GRO GRO-α l-309 IL-1α IL-1β 
3 IL-2 IL-3 IL-4 IL-5 IL-6 IL-7 IL-8 IL-10 IL-12  IL-13 IL-15 IFN-γ 
4 IL-2 IL-3 IL-4 IL-5 IL-6 IL-7 IL-8 IL-10 IL-12  IL-13 IL-15 IFN-γ 
5 
MCP-
1 
MCP-
2 
MCP-
3 MCSF MDC MIG MIP-1δ RANTES SCF SDF-1 TARC TGF-β1 
6 
MCP-
1 
MCP-
2 
MCP-
3 MCSF MDC MIG MIP-1δ RANTES SCF SDF-1 TARC TGF-β1 
7 
TNF-
α 
TNF-
β EGF IGF-1 Angiogenin Oncostain M Thrombopoietin VEGF 
PDGF 
BB Leptin Neg Pos 
8 
TNF-
α 
TNF-
β EGF IGF-1 Angiogenin Oncostain M Thrombopoietin VEGF 
PDGF 
BB Leptin Neg Pos 
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Figure 4-1B Cytokine Blot Array 
 
Figure 4-1A) Cytokine blot array grid, Pos; positive: Neg; negative: ENA-78; epithelial-derived 
neutrophil activating protein 78: GCSF; granulocyte colony stimulating factor: GM-CSF; 
granulocyte-macrophage colony stimulating factor: GRO; growth-related Oncogene: I-309; 
inflammatory cytokine I-309: IL; interleukin: IFN; interferon: MCP; monocyte chemo-attractant 
protein: MCSF; macrophage colony stimulating factor: MDC; macrophage-derived chemokine: 
MIG; monokine induced by gamma interferon: MIP; macrophage inflammatory protein: 
RANTES; regulated upon activation, normally T-expressed, and presumably secreted: SCF; stem 
cell factor precursor: SDF; stromal cell-derived factor 1: TARC; thymus and activation-regulated 
chemokine: TGF; transforming growth factor: TNF; tumor necrosis factor: EGF; epidermal 
growth factor: IGF-1; insulin-like growth factor 1: VEGF; vascular endothelial growth factor: 
PDGF BB; platelet-derived growth factor beta polypeptide BB. Figure4-1B) Cytokine blot array 
hybridized with serums from septic patients and healthy individuals. 
NA NB NC ND 
SE SF SG SH 
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Table 4-2: Cytokine Blot Array 
Protein Classification Patient 
SE 
Patient 
SF 
Patient 
SG 
Patient 
SH 
Interferon γ Pro-inflammatory 125.3 --- 24.4 --- 
Interleukin 15 Pro- inflammatory --- --- --- 7.9 
Interleukin 1 beta Pro- inflammatory --- --- 736.7 --- 
Interleukin 7 Pro- inflammatory --- --- --- 149.6 
Tumor necrosis factor α Pro- inflammatory 1738.5 781.2 875.8 955.9 
Interleukin 6 Pro- and anti- inflammatory --- --- 146.0 1188.2 
Interleukin 10 Anti- inflammatory --- --- --- 126.1 
Interleukin 13 Anti- inflammatory --- --- --- 4.8 
Interleukin 5 Anti- inflammatory --- --- 27.9 19.2 
Growth-related oncogene Chemokine --- 10.8 2.9 22.0 
Growth-related oncogene alpha Chemokine --- --- --- 5.4 
Interleukin 8 Chemokine --- 9.0 --- 34.4 
monocyte chemo-attractant protein 1 Chemokine --- 7.2 13.2 17.9 
monocyte chemo-attractant protein-2 Chemokine --- --- --- 4.3 
monokine induced by gamma 
interferon 
Chemokine --- --- --- 3.8 
macrophage inflammatory protein 5 Chemokine --- --- 2.4 --- 
stromal cell-derived factor 1 Chemokine --- --- --- 2.1 
Thymus and activation-regulated 
chemokines 
Chemokine --- 5.8 --- --- 
Angiogenin Other cytokine 0.4  --- --- 
epidermal growth factor Other cytokine 7.9 7.3 --- --- 
Leptin Other cytokine 8.0 --- --- 8.4 
Platelet derived growth factor-BB Other cytokine --- 7.1 --- --- 
Relative levels of protein expressed in the sera of septic patients compared to healthy 
individuals. --- indicates no difference between levels found in the septic sera when compared to 
the healthy sera.
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4.4 Discussion 
Cytokines, chemokines and growth factors play important roles at the molecular level during 
sepsis.  They play a direct role, such as IL-1β which can induce apoptosis or an indirect role such 
as chemokines which attract leukocytes to the site of infections which in their turn release other 
mediators of inflammation to further activate the host response to inflammation.  By determining 
the expression patterns and levels of key cytokines, chemokines and growth factors we will be 
able to develop informed targeted therapeutic strategies. 
4.4.1 Pro-inflammatory cytokines.   Increased production of inflammatory mediators can lead to 
tissue injury and organ failure [306].  It has been shown that mammals respond to endotoxins 
such as lipopolysaccharide (LPS) from Gram-negative bacteria and exotoxins such as toxic 
shock syndrome toxin 1 (TSST-1) from Gram-positive bacteria, by producing a variety of 
immune cell mediator such as TNF-α and IL-1β which have been shown to trigger lethal shock.   
In our study, pro-inflammatory cytokines were elevated in septic patients when compared to 
healthy individuals.  TNF-α, IL-1β, IFN-γ, IL-7 and IL-15 were modulated during sepsis, 
although the level of each cytokine varies from one patient to another.  TNF-α was the only pro-
inflammatory cytokine observed to be greatly increased in all four septic patients on the blot 
array with induction levels of 1738.5, 781.2, 875.8 and 955.9 for patient SE, SF, SG and SH 
respectively (Table 4-2).  IFN-γ was significantly increased in two of the four patients on the 
cytokine blot array, patient SE with a 125.3-fold increase and patient SG with a 24.4-fold 
increase.  In contrast, IL-1β was only elevated in patient SG by 736.7 fold while IL-7 and IL-15 
were only elevated in patient SH with increases of 149.6- and 7.9-fold respectively. 
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4.4.1.1 Tumor necrosis factor-alpha (TNF-α).  TNF-α was the only factor on the array found to be 
significantly up regulated in all four septic patients when compared to healthy individuals.  It is 
often characterized as the prototype of a host damaging cytokine [307,308].  TNF-α has been 
shown to be one of the first cytokine secreted during sepsis.  It is a potent activator of 
inflammation reactions of the innate immune system, including induction of cytokine production, 
activation and expression of adhesion molecules and growth stimulation [303,309].  Supporting 
the data on this cytokine array, previous studies have also demonstrated elevated pro-
inflammatory cytokines, including TNF-α in septic patients and animal models of sepsis 
[300,303]. In addition it has also been demonstrated that infusion of TNF-α into animals induced 
characteristic septic symptoms while neutralizing TNF-α impaired the host defence against 
pathogens [307,310]. 
At low concentrations, TNF-α is involved in the maintenance of homeostasis of the immune 
system.  It has many protective roles and biological functions as part of the physiological host 
defence against infections, trauma, or ischemia, including cell proliferation, differentiation, 
apoptosis, lipid metabolism, and coagulation [311].  In contrast, excessive TNF-α production, as 
observed during sepsis leads to a harmful and often lethal systemic endotoxin like response 
which includes fever, hypotension, lactic acidosis, disseminated intravascular coagulation, shock, 
organ failure and death [312].  Multiple organ failure in patients with septic shock is often 
characterized by increased apoptosis throughout the body of lymphocytes and macrophages 
[166].  The apoptosis in septic shock appears to be triggered by signalling via members of the 
TNF-α receptor family [313], and induces activation of the Fas-associated death domain and 
caspase machinery [314]. The levels of TNF-α observed in the septic sera on our antibody array 
were extremely high when compared to the levels found in the healthy sera, and thus supports 
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the notion that extremely high levels of this cytokine activates apoptosis which plays a major 
role in tissue damage and organ failure during sepsis. 
Massive TNF-α release can activate in turn other mediators of the inflammation cascade 
including higher expression levels of pro-inflammatory cytokines, anti-inflammatory cytokines 
and chemokines that all in concert participates in the pathogenesis of sepsis and septic shock 
[172].   On the antibody array, we demonstrated that other cytokines and chemokines such as IL-
1β, IL-10, IL-6 and IL-8 are also modulated in the sera of septic patients which could be partly 
due to TNF-α’s activation.  Its commonality in all patients may imply that TNF-α is needed in a 
variety of responses to different infections.  The other pro-inflammatory cytokines were 
differentially modulated between the different septic patients.  IL-1β is modulated in patient SG, 
IFN-γ is modulated in patient SE and SG, while IL-7 and IL-15 are modulated in patient SH 
only. 
4.4.1.2 Interleukin-1 beta (IL-1β).  IL-1β, was induced in patient SG by 736.7-fold (Table 4-2).  It 
has been shown to be induced by nearly all microbes and microbial products [315] and is an 
important mediator of the inflammatory response.  IL-1β is produced by activated macrophages 
as a proprotein and is proteolytically processed to its active form by caspase 1 (CASP1/ICE).  It 
is involved in a variety of cellular activities, including cell proliferation, differentiation, and 
apoptosis.  Also, similarly to TNF-α, IL-1β also increases the expression of other cytokines, such 
as TNF-α, IL-6 and IL-8.  The increased production of other cytokines modulated by IL-1β 
exacerbates the uncontrolled systemic inflammation observed during sepsis.  
In addition, IL-1β has been shown to activate neutrophils which induce a shock-like state in 
animal models [316]. In different models of local systemic inflammation, both in vitro and in 
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vivo, IL-1β acts synergistically with TNF-α [317] by increasing apoptosis and other mediators of 
inflammation. IL-1β, even though not greatly increased in all the serums of septic patients, might 
contribute synergistically with high levels of TNF-α, to increase the harmful effects observed 
during sepsis. 
Increased plasma IL-1β has been reported in patients with various infections, in patients with 
sepsis and septic shock, as well as in healthy individuals injected with LPS [318]. Clinical trials 
using intravenous IL-1Ra, which was shown to block IL-1β activity were performed without 
reaching a statistically significant reduction in mortality even though in animal models of 
systemic inflammation (such as in septic shock), specific blockade of IL-1β with IL-1Ra resulted 
in a reduction in the severity of the inflammation [316,317]. These treatments were not effective 
and the reasons for this could be due to varying levels of IL-1β in different patients and also to 
the different pattern in cytokine expression in the sera as observed in our blot arrays.  Patients 
with low IL-1β levels would not be expected to respond to a treatment using IL-Ra. 
4.4.1.3 Interferon-gamma (IFN-γ).  IFN-γ is a pro-inflammatory cytokine regulated by other 
cytokines such as TNF-α and IL-4 [319].  Elevated levels of  IFN-γ were observed in the sera of 
septic patients SE (125.3-fold increase) and SG (24.4-fold increase) (Table 4-2). IFN-γ plays a 
complex and central role in the resistance of mammalian hosts to pathogens by activating several 
important antimicrobial effector functions in macrophage and neutrophil, including tumour cell 
cytotoxicity, antimicrobial activity, and the induction of specific MHC antigens, which increases 
receptor-mediated phagocytosis and pathogen killing [320].  IFN-γ also up-regulates the 
expression of chemokines and adhesion molecules which helps to direct leukocytes to sites of 
infection [321].  
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IFN-γ is an important immunomodulatory agent that is stimulated during infection and is of 
critical importance in the aid in host defence after the onset of sepsis.  Nevertheless studies have 
shown that excessively high levels are deleterious [306,322].  IFN-γ antibody decreases bacterial 
load and attenuates mortality in various models of sepsis, thus implicating IFN-γ in the lethality 
of the disease [322,323].  In addition, mice lacking a functional IFN-γ response have been 
reported to have decreased natural resistance to infections [320,324]. These studies confirm that 
an impaired IFN-γ production is associated with worsened patient outcome during sepsis 
[320,325].  Lower levels of IFN-γ during sepsis can be detrimental by decreasing the clearing of 
bacteria and bacterial products which favors a greater uncontrolled infection.  Increased 
production of IFN-γ can also be deleterious during sepsis by increasing the production of other 
inflammatory cytokines and the production of nitric oxide thus favoring the uncontrolled 
systemic inflammatory response [326].  
4.4.1.4 Interleukin-7 (IL-7).  When immune system is first challenged by exposure to antigen, 
naïve T cells become activated and undergo rounds of expansion as they differentiate into 
effector cells [327].  T lymphocytes play central roles in all adaptive immune responses against 
protein antigens by recognizing and killing cells infected with intracellular viruses and microbes 
[326]. T-cell population has been shown to be dependent on the presence of IL-7 for its 
persistence and survival, thus, IL-7 is now known as a central regulator of homeostasis for T 
lymphocytes [328].  Patient SH showed a 149.6-fold increase of IL-7 when compared to healthy 
individuals.  Homeostasis of peripheral T cells through IL-7 is achieved by a combination of 
programmed or regulated cell death and responses to survival factors [327]. IL-7, while inducing 
the proliferation and differentiation of immature thymocytes, it stimulates the expressions of the 
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anti-apoptotic gene Bcl-2 in order to protect thymocytes from apoptosis [329]. Circulating levels 
of IL-7 increase in response to T-cell depletion suggests a role in T-cell regeneration [330]. 
In addition, IL-7 and IL-15 augment natural killer (NK) cell function [331] while certain 
precursor B-lymphocyte cell lines rapidly undergo apoptotic cell death following IL-7 
withdrawal which could be detrimental during sepsis because mature B lymphocyte help secrete 
antibodies necessary to clear the infection [332].   
4.4.1.5 Interleukin-15.  IL-15, is involved in numerous processes, including recruitment and 
activation of T cells, maintenance of T cell memory, activation and proliferation of B cells and 
natural killer, activation of neutrophils, and inhibition of apoptosis [333]. We observed on the 
array an up-regulation by 7.9 fold in the serum of patient SH when compared to the levels in the 
serum of healthy individuals.  IL-15, similarly to IL-7, is produced by macrophages in a wide 
variety of tissues after stimulation with LPS and in infections with various microorganisms in 
mice and humans [334].  
IL-15 is a potent inhibitor of several apoptotic pathways in vitro on activated human T and B 
cells in response to various stimuli [314,335].  It inhibits apoptosis via the induction of the anti-
apoptotic molecules Bcl-2 through activation of transcription factors STAT-5 and c-Myb 
[329,336].  IL-15 also inhibits TNF-α-mediated apoptosis by blocking the adaptor protein 
recruitment TRAF2 to the TNR1 [337].  Thus, IL-15 is a powerful apoptotic antagonist and can 
help prevent multiple organ failure caused by increased apoptosis observed during sepsis and 
septic shock [314].  This is supported by a study showing that IL-15 over-expression in mouse 
model can prevent TNF-α-induced apoptosis and protect against E. coli-induced shock [314].  
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Consequently, the up-regulation of this pro-inflammatory cytokine, suggest a protection against 
TNF-α mediated apoptosis which is greatly increased during sepsis, while a decreased expression 
of IL-15 during sepsis would increase the risk of organ failure due to increased apoptosis. 
4.4.1.6 Interleukin-6 (IL-6).  IL-6 is a pleiotropic cytokine with a wide range of biological 
activities that has been shown to possess both pro-inflammatory and anti-inflammatory 
properties.  IL-6 was elevated by 146.0 and 1188.2 fold in septic patient SG and SH (Table 4-2) 
when compared to healthy individuals. Conventionally, IL-6 is considered to be a pro-
inflammatory cytokine based on its pyrogenicity and its ability to induce a hepatic, acute-phase 
protein response.  IL-6 also appears to down-regulate TNF-α expression with would categorize it 
as an anti-inflammatory cytokine [338]. 
IL-6 is synthesized by a wide range of cells including mononuclear phagocytes, 
monocytes/macrophages, vascular endothelial cell, fibroblasts, and T cells in response to 
endotoxin, IL-1β and TNF-α.[339] It has been demonstrated to regulate immune reactivity, the 
acute-phase response and inflammation which makes it also is a key mediator in multiple organ 
failure during sepsis [340]. IL-6 is the primary factor responsible for the induction of a broad 
array of acute phase proteins in response to systemic injury or inflammation [175] such as α-1-
acid-glycoprotein or C-reactive protein.  In contrast, IL-6 has also been demonstrated to induce 
direct in vitro myocardial depression in several models of sepsis, although not in others 
[175,341].  Thus, IL-6 appears to be both a marker and a mediator of sepsis [340].   
Plasma IL-6 concentration has been directly correlated with risk of death due to sepsis [317,342], 
but it has been also demonstrated that the persistent elevations in IL-6 appears to be important 
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than initial or peak levels in terms of outcome during sepsis [340,343]. The up-regulation seen 
on the blot array further indicates IL-6 involvement during sepsis in a number of patients. 
4.4.2 Anti-inflammatory cytokines.   
During the later stage of sepsis, anti-inflammatory mediators are produced to counteract the pro-
inflammatory effects induced during the early phase [311].  Anti-inflammatory cytokines can 
either impair the local antibacterial effectors mechanisms or can diminish systemic toxicity 
produced by bacteria depending on expressed levels [344].  In our cytokine blot array, three anti-
inflammatory mediators were observed to be up-regulated in different septic patients.  These 
anti-inflammatory cytokines include IL-10, IL-13 and IL-5. 
4.4.2.1 Interleukin-10 (IL-10), Interleukin-13 (IL-13).  IL-10 and IL-13 have pleiotropic effects in 
immunoregulation and inflammation. The expression of both cytokines is modulated by a variety 
of cell types, including T cells, monocytes/macrophages, dendritic cells, and epithelial cells. 
They are potent anti-inflammatory cytokines that suppresses macrophage inflammatory functions 
during sepsis which subsequently prevents the production of TNF-α, IL-1β, IFN-γ, IL-8 and IL-
12 [302,345]. IL-10 and IL-13 have been observed to be up-regulated by 126.1- and 4.8-fold 
respectively in the serum of patient SH (Table 4-2).   
IL-10 and IL-13 act as feedback regulator by initially being induced by the initial pro-
inflammatory mediators, such as TNF-α and IL-1β and then subsequently, their endogenous 
production inhibits NF-κB production thus suppressing endogenous TNF-α, IL-1β and 
chemokine synthesis [344,346].  In addition, monocyte deactivation observed in sepsis is 
partially due to IL-10, while augmented substrate adherence of monocyte due to IL-13 [347]. 
Furthermore, both IL-10 and IL-13 enhance B cell survival, proliferation, and antibody 
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production. In addition, IL-10 also induces neutrophils apoptosis during the resolution of 
inflammation [348]. 
During sepsis, the administration of anti-IL-10 antibodies can increases endotoxin and bacteria-
induced mortality in mice, whereas the systemic injection of IL-10 have been shown to prevent 
septic shock in animals by inhibiting the synthesis of TNF-α, IL-1β, IL-6, IL-8, IFN-γ and others 
[349]. Also, blocking IL-13 was detrimental to survival after cecal ligation and puncture (CLP), 
further indicating that it also serves as a protective cytokine during the evolution of sepsis [350].   
While increased levels of IL-10 and IL-13 have been shown to be beneficial and vital for 
survival during sepsis by contributing to the immunosuppressive effects [300], it can also, in 
other cases, be detrimental by enhancing the inflammatory response.  Studies also reported that 
the highest level of IL-10 relative to those of TNF-α was associated with poor outcome in sepsis 
patients [347,351]. 
4.4.2.2 Interleukin-5 (IL-5).  IL-5 enhanced B cell survival, proliferation and antibody production 
is known to enhance humoral immunity and inhibit cell-mediated immunity, which result in 
protective effect for pathogens removed primarily through humoral mechanisms [352].  Studies 
have also shown that IL-5 is augmented significantly following anti-parasite therapy treated 
patients [353].  Although there are very few studies that directly link IL-5 with sepsis, we found 
that this cytokine was significantly up-regulated in the serum of patients SG and SH by 27.8- and 
19.2-fold respectively.  This suggests that this cytokine might be linked the anti-inflammatory 
processes during sepsis and septic shock.  Further studies are needed to determine the precise 
role of IL-5 during this disease. 
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4.4.5 Chemokines.  Chemokines are small chemotactic cytokines involved in immunoregulation 
and inflammation processes.  They are a large superfamily of structurally and functionally 
related molecules that induce directional migration and activation of specific leukocyte 
population from the vasculature into the tissue during inflammation [354].  Chemokines are 70-
90 amino acids in length and are divides into four subfamilies, C, CC, CSC and CXC, based on 
their conserved cysteine residues located near the amino terminus relative position of their 
cysteine residues [354]. 
There are at least 50 distinct chemokines, which participate in recruiting different leukocyte 
population to the site of inflammation [354].  CXC chemokines, which include GRO and IL-8, 
are potent chemoattractants for neutrophils, whereas the CC chemokines, including MCP-1, and 
MIP-1, can attract monocytes, lymphocytes, basophils, eosinophils and natural killer cells [355].   
In this study, we measured elevated levels of many chemokines in three of the septic patients.  It 
was previously shown that many chemokines are up-regulated simultaneously upon LPS-
stimulation which is consistent with our result [356]. Also, this elevation indicates that a wide 
variety of chemokines may orchestrate under pathophysiological conditions and play a role in 
inflammatory reactions [356].  In addition, another study measured extremely high levels of all 
chemokines in the serum during acute-phase.  The levels were also shown to be significantly 
higher in non survivors compared with survivors and in patients with septic shock compared with 
patients with sepsis [355].   In this study we observed an up-regulation of chemokines with fold 
increase that range from 2.4- to 13.2-fold which further emphasize the importance of chemokines 
in recruiting leukocytes during the course of sepsis. 
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4.4.5.1 Interleukin-8 (IL-8).  One of the chemokines expressed on the array, IL-8, also known as 
CXCL8, is a chemotactic factor for neutrophils, basophils, and T-cells during the inflammatory 
response [357]. Chemokine levels, including MCP-1 and IL-8 have been correlated with LPS 
plasma level, which further suggests their important role during sepsis [358].  IL-8 was shown to 
be undetectable in the serum of our healthy volunteers while it was elevated in two of the septic 
patients, SF and SH, by 9.1- and 34.4-fold correspondingly.     
IL-8 is released from several cell types in response to multiple inflammatory stimuli including 
pro-inflammatory cytokines such as TNF-α and IL-1β [357,359].  During inflammation, IL-8 
levels will sustain for a prolong period of time when compared to other cytokine which are 
typically produced and cleared in a matter of a few hours [357]. IL-8 will initially mediate the 
migration of leukocytes across the vascular endothelium [359].  Once leukocytes are present in 
the tissue, neutrophils are activated by IL-8 to produce oxygen free radicals, release proteases 
and begin to phagocytose and kill ingested pathogens [360].  IL-8 will also inhibit neutrophil 
adhesion to cytokine-activated endothelial cells, which protects these cells from neutrophil-
mediated damage [359]. 
Although IL-8 attract neutrophils during local inflammation in order to increase the 
inflammation process, during sepsis, increased levels of IL-8 are found in the plasma which will 
produce a gradient away rather than in the direction of the initial inflammation [356,357].  This 
anti-inflammatory role caused by the recruitment of leukocyte in the plasma versus the local 
infection makes clearing of the infection a greater challenge during sepsis.  The opposed gradient 
will reduce recruitment of neutrophils at the site of inflammation thus limiting the effect of the 
pro-inflammatory mediators released by these cells. This is supported by a study where injection 
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of IL-8 in rabbits and rats significantly reduced in vivo neutrophil migration towards 
inflammatory foci [361].  
This chemokine has been shown to be significantly higher during multiple organ failure, in non 
survivors compared with survivors and in patients with septic shock compared with patients with 
sepsis [355,362].  It is rapidly synthesized during inflammation where it acts to recruit and 
activate acute inflammatory cells [357]. 
4.4.5.2 Monocyte chemo-attractant protein 1 (MCP-1/CCL2) and Monocyte chemo-attractant 
protein 2 (MCP-2/CCL8).  MCP-1 has a chemotactic activity for monocytes and basophils, while 
MCP-2 has a chemotactic activity for monocytes, lymphocytes, basophils and eosinophils.  Both 
chemokines are expressed in multiple cell types, including fibroblasts, endothelial cells, 
monocytes, and macrophages following stimulation with TNF-α, IL-1β, IFN-γ or endotoxin, 
which
 
are all involved in the pathogenesis of sepsis [356,363,364].  We observed increased levels 
of MCP-1 in the serum of patients SF, SG and SH by 7.2-, 13.2- and 17.9-fold respectively, 
while MCP-2 was increase in patient SH by 4.3-fold (Table 4-2).  
Mice challenged with Gram-negative bacteria which were administered MCP-1 have showed a 
diminished lethality to endotoxemia [365].  This indicates that the increased levels of MCP-1 and 
possibly MCP-2 found in septic patients may furthermore constitute a host compensatory 
response to reduce the deleterious effects of sepsis development [364].  In contrast to MCP-1, 
MCP-2 did not show an increase in patients with Gram-negative infections compared with 
controls, although it was showed to be increased in almost all Gram-positive infections [364].  
Consistent with our results, MCP-1 when expressed exerts a protective role during sepsis 
triggered by both Gram-positive and Gram-negative bacteria, by eliciting and recruiting various 
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leukocyte subpopulations required
 
to locally contain the primary traumatic insult and eliminate 
microbes [363].  In addition, MCP-2 was only shown to be up-regulated in the only patient who 
survived with a Gram-positive infection, further suggesting an added beneficial effect due to 
MCP-2 expression in Gram-positive infections. 
In contrast, other studies also showed that extremely high levels of MCP-1 and MCP-2 in the 
sera of patients with sepsis correlated with the more severe forms of sepsis and also was 
significantly higher in non survivors compared to survivors during sepsis and septic shock 
[355,358,364].  Blocking MCP-1 significantly
 
decreased the survival rate in animal model of 
sepsis because of increased viability of bacteria due to the reduction in the recruitment and 
activation of leukocytes [363].  This implicates MCP-1 and perhaps MCP-2 in the pathogenesis 
of sepsis.  These studies support the notion that a well-regulated expression of MCP-1 and MCP-
2 levels is beneficial to the host, while overexpression or under expression might be detrimental.   
The up-regulation observed on our antibody array further supports previous studies showing an 
up-regulation of these chemokines during sepsis and septic shock. 
In addition, anti-TNF-α treatment during endotoxemia caused inability of the myocardium to 
block IL-6 and MCP-1 expression which suggests another possible mechanism for the failure of 
anti-TNF-α therapies in the treatment of endotoxin shock and further emphasizes the complex 
nature of this multifaceted disease.  
Growth-related oncogene alpha (GRO-α/CXCL1), Growth-related oncogene beta (GRO-
β/CXCL2), Growth-related oncogene gamma (GRO-γ/CXCL3).  GRO-α, -β, and -γ are CXC 
chemokines which are a family of chemokines that are specialized in monocyte arrest and that 
have neutrophil-activating and chemoattractant properties similar to those of IL-8 [366] GRO-α 
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was increased in the serum of patient SH by 5.4-fold while GRO β, and γ was observed to be 
increased in the serum of patients SF, SG and SH by 10.8-, 2.9- and 22.0-fold respectively. 
GRO-α, β, and γ all act, through the CXCR2 receptor, as arrest chemokines for monocyte 
adhesion in various models of inflammation although they are unable to induce monocyte 
chemotaxis [366].  In addition, platelet activation leads to the release of GRO-α, which then 
attracts leukocytes and further activates other platelets [367].   This function provides a rapid 
essential protection against bleeding and in addition, catalyzes the slower formation of stable 
blood clots through the coagulation cascade [367].  
GRO α, GRO β (MIP-2α), and GRO γ (MIP-2β) have shown to be expressed in response to a 
variety of inflammatory mediators, such as IL-1β, TNF-α, IFN-γ and LPS, in monocytes, 
fibroblasts, melanocytes and epithelial cells [356]. During sepsis, it was reported that an altered 
chemotaxis of neutrophils to GRO family was associated with a decreased expression of CXCR2 
on various cells [368].  Thus during sepsis, the decrease of neutrophils to site of infection might 
be due indirectly to the GRO family since the receptor is decreased.   
Accordingly, the elevated expression of GRO-α, GRO-β and GRO-γ in the serum of septic 
patients might be linked to a decreased expression of CXCR2 and to increased levels of others 
cytokines secreted during inflammation such as TNF-α, IL-1β, IFN-γ during sepsis. 
4.4.5.3 Thymus and activation-regulated chemokines (TARC/CCL17).  TARC (CCL17) is a CC 
chemokines with chemotactic activity for T lymphocytes, but not monocytes or granulocytes 
(136).  TARC’s receptor, CCR4 is highly expressed on Th2 cells and thus TARC is considered to 
by a key mediator in recruiting these cells [369,370].   The blot array showed that TARC was 
elevated by 5.8-fold in patient SF which further indicates the important role of chemokines 
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during sepsis. In addition, this chemokine plays an important role in T cell development in the 
thymus as well as in trafficking and activation of mature T cells.   
During sepsis, coagulation abnormalities are common [371].  Platelet aggregation studied during 
sepsis give conflicting results.  Studies have shown an increased platelet aggregation [372] while 
other studies have shown an inhibited platelet aggregation [373].  TARC, which is produced 
during inflammatory responses, coupled with low levels of ADP or thrombin, can serve as strong 
rapid activators of platelet aggregation and adhesion after its binding to CCR4 [374].  TARC 
consequently stimulates platelet shape change, aggregation, and adhesion to collagen or
 
fibrinogen in addition to attracting T lymphocytes and B lymphocytes [374,375].  
TARC gene expression was shown to be up-regulated simultaneously with many other 
chemokines upon LPS-stimulation [356,376].   TARC mediates selective migration of Th2 cells 
into inflamed tissues.  In addition, CCR4 has been shown to play a key role in models of sepsis 
in that CCR4 deficient mice exhibited significantly decreased mortality on administration of high 
or low dose bacterial LPS compared with mice with the CCR4 receptor suggesting a protective 
role for TARC and its receptor in sepsis [377]. 
In addition the similar roles of TARC and GRO family chemokines during sepsis further 
indicates that there are overlapping and redundant roles between chemokines during the disease.  
4.4.5.4 Stromal cell-derived factor-1 (SDF-1/CXCL12).  SDF-1 is a chemokine with chemotactic 
role for T lymphocytes, monocytes, and neutrophils, which all express CXCR4, the only known 
receptor for SDF-1 [354].  SDF-1 and CXCR4 together play crucial roles in many biological 
processes including hematopoiesis, cardiogenesis, vasculogenesis, neuronal development and 
immune cell trafficking [378]. On our blot array, patient SH had an increase of SDF-1 expression 
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in the serum by 2.1-fold (Table 4-2) when compared to healthy individuals.  Stromal cell-derived 
factor (SDF-1) activates leukocytes in response to pro-inflammatory stimuli such as LPS or 
TNF-α. Thus, inhibiting SDF-1 or its receptor CXCR4 disrupts normal immunological response 
by deregulated lymphocyte trafficking.  
The response of Toll-like receptor 4 (TLR4) to LPS is thought vital for resisting infection while 
aberrant TLR4 signalling may initiate inflammatory conditions including sepsis syndrome [379]. 
It was observed that TLR4 signalling is enhanced when CXCR4 is blocked and suppressed TLR4 
signalling occurs with an increased expression of CXCR4 [379]. Therefore, CXCR4 exert local 
control of TLR4 and this suggests that SDF-1/CXCR4 expression suppresses TLR4 signalling 
and lead to increased infection. 
High levels of expression of IL-10, TNF-α and IFN-γ down regulate CXCR4 expression, thus 
indirectly reducing SDF-1 expression [350].  In addition, other studies have also shown that the 
expression of SDF-1 is unaltered by certain inflammatory stimuli [381] suggesting that the 
expression of SDF-1 might be dependent on the infecting organism. 
4.4.5.5 Monokine induced by gamma-interferon (MIG/CXCL9).  MIG was up-regulated in patient 
SH by 3.8-fold when compared to healthy individuals.  Its function has not been specifically 
defined; however, unlike many CXC chemokines, MIG is thought to be involved only in T cell 
trafficking.  MIG does not share receptors with any other chemokines and is recognized only by 
CXCR3 receptor that has only been found on T lymphocytes.  Thus it is thought that MIG is 
selective for activated T-lymphocytes and it may be inferred that the states of viral infection may 
be regulated via MIG receptor expression [382].     
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IFN-γ stimulated mononuclear cells have been shown to induce a sustained expression of 
Monokine induced by interferon-γ (MIG/CXCL9) which then attracts activated T-cells through 
its chemokine receptor CXCR3 [381,382].  Also, MIG, similarly to SDF-1, was showed to be 
enhanced during the early and late stages of infection in cardiac tissues of animals infected with 
Tripanosoma cruzi [381]. 
However it was shown that targeting MIG alone does not directly modulate the inflammatory 
response within the heart.  This suggests that other inflammatory mediators are able to regulate 
inflammation in this tissue [383]. 
4.4.5.6 Macrophage inflammatory protein 5 (MIP-1δ/CCL15).  MIP-1δ (CCL15) is a CC 
chemokines that attract T cells, monocytes, neutrophils and eosinophils [384].  MIP-1δ binds to 
receptors CCR1 and CCR3 on various cells inducing signalling which can alter the intracellular 
calcium concentration in these cells [385].  This chemokine was increased in patient SG by 2.4-
fold (Table 4-2). 
Activator protein-1 (AP-1) and nuclear factor-kappa B (NF-κB) (through c-Jun N-terminal 
kinase (JNK)/mitogen activated protein kinase (MAPK) and MAPK extracellular kinase (MEK) 
pathways) regulates the transcription of MIP-1δ in monocytoid cells [384].  MIP-1δ has been 
shown to be expressed in response to oxidative stress [384] and in addition, neutrophils in the 
plasma release CCL15 proteolytically in order to induce monocyte infiltration into sites of 
inflammation [368].  
The expression of MIP-1δ during sepsis has not been extensively studied and thus its exact role 
during the process of this disease is unknown.  We observed an elevated level of this chemokine 
in patient SG.  
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4.4.6 Others. 
Other factors included on the blot array cannot be classified under the pro-inflammatory, the 
anti-inflammatory or the chemokines categories.  These factors which are growth factors, 
angiogenic factors, and hormones possess many characteristic of cytokines.  These factors 
specifically are leptin, epidermal growth factor (EGF), angiogenin, and platelet derived growth 
factor-BB (PDGF-BB).  These factors were elevated in the septic sera, with the exception of 
angiogenin which showed a down-regulation, in the different septic patients.  
4.4.6.1 Leptin.  Leptin, originally described as an antiobesity hormone, was found after extensive 
research, to be a crucial cytokine during inflammation and sepsis [387].  Leptin was shown to 
modulate monocyte-macrophage function and to regulate pro-inflammatory response [388].  On 
our blot array we observed an increased serum leptin level in patient SE (8.0-fold increase) and 
patient SH (8.4-fold increase) when compared to the healthy individuals (Table 4-2).   
It was shown that TNF-α and IL-1β are both potent inducers of leptin in mouse macrophages, 
which results  in an enhanced cytokine production, including IL-6, IL-1β and TNF-α [388]. 
Other studies in relation to leptin showed that both TNF-α and leptin depress ventricular 
myocyte shortening (inhibition of cardiac myocyte contraction), which is likely mediated 
through a nitric oxide (NO)-dependent mechanism [389].  In addition, during the impaired 
myocyte contraction, leptin and TNF-α showed no synergistic or additive effect between the two 
mediators [389].  Since increased leptin concentration has been reported during sepsis [389], this 
could imply that leptin may induce sepsis dependent myocardial dysfunction by depressing 
myocyte contraction. 
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4.4.6.2 Epidermal growth factor (EGF).   Epidermal growth factor (EGF) has a profound effect on 
the differentiation of specific cells in vivo.  It is a potent mitogenic factor for a variety of cultured 
cells of both ectodermal and mesodermal origin.  EGF is known to activate epithelial cell 
migration and proliferation and in addition, accelerates wound and ulcer healing in vivo and in 
vitro [390].  In addition, EGF was shown to reduce bacterial translocation and blood infection 
when administered to rats receiving total parenteral nutrition [391].  Studies have not been 
performed to determine the role of EGF during sepsis.  Here, we have shown that EGF levels are 
elevated in patient SE and SF by 7.9- and 7.3-fold respectively.   
4.4.6.3 Angiogenin.  Angiogenin a heparin-binding 14 kDa plasma protein with angiogenic and 
ribonucleolytic activity and is part of a family of endogenous antimicrobial proteins [392].  
Interestingly, it was observed to be down-regulated in the serum of septic patient SE (2.2 fold 
decrease) when compared to the serum of healthy individuals.  Angiogenin has been shown to 
induce a wide
 
range of cellular responses necessary for angiogenesis by interacting with 
endothelial cells which including migration, proliferation, and tube formation [393]. In addition, 
human angiogenin, which can be induced during inflammation, exhibits microbicidal activity 
against systemic bacterial and fungal pathogens.  The activity observed during inflammation 
suggests that angiogenin might contribute to systemic responses to infection [392].  The down-
regulation observed in septic patients further suggests that angiogenin has important microbicidal 
activity.  Lower microbicidal activity during sepsis leads to an increase bacterial load in the 
blood and to a less favourable outcome. 
4.4.6.4 Platelet derived growth factor-BB (PDGF BB).  Platelet derived growth factor-BB (PDGF 
BB) was observed to be increased by 7.1-fold in patient SF.  PDGF BB is a member of the 
platelet-derived growth factor family and affects the process of normal wound healing.  Shortly 
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after wounding, platelets within the fibrin plug releases PDGF-BB.  Thereafter, PDGF-BB 
amplifies fibroblast expression and activates epithelial cell migration and proliferation, which are 
involved in wound healing [390].  
The efficacy of PDGF is shown in various clinical trials involving pressure, neuropathic ulcer 
healing, and surgical wounds [394]. A preliminary study suggests that Becaplermin (PDGF-BB), 
the only growth factor approved by the Food and Drug Administration accelerates healing of 
separated surgical wounds [395]. 
PDGF BB, similarly to TARC, plays an important role in wound healing.  Thus, further research 
is needed to investigate the role between sepsis and wound healing growth factors. 
4.5 Conclusion 
Various microbes and microbial products initiate host cellular signalling pathways that produce a 
surge of pro-inflammatory mediators.  This is followed by chemokine production which 
regulates migration of cells and by an anti-inflammatory response to attenuate the initial 
response.  In order to resolve the infection, the balance between the pro-inflammatory, the anti-
inflammatory and the chemokine response must be tightly regulated.  An imbalance or a 
deregulation of one or multiple factors of the response can lead, through multiple pathways, to 
cellular dysfunction, tissue injury, organ dysfunction, multiple organ failure and possibly death.   
Interestingly, the only cytokine that was consistently elevated in the serum of septic patients 
when compared to normal is the pro-inflammatory cytokine TNF-α which further highlights its 
importance in the various pathways that are deregulated during the disease. Although the 
expression of the factors during sepsis varies from one patient to the other, our data indicate that 
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multiple key cytokines, chemokines and growth factors are expressed.  Targeting a single factor 
during sepsis is insufficient in re-establishing a balanced and beneficial inflammatory response 
due to the multiple and overlapping cascades activated during the disease.  We believe that 
individual and specific therapies will be developed by profiling the cytokine, chemokine and 
growth factor pattern of each patient. 
It is worth noting that investigating the change in profile of these pro and anti-inflammatory 
mediators would be beneficial in identifying patterns of expression that may be used to predict 
progression of sepsis. Temporal changes in these mediators could also be used to identify 
synergistic combinations that would be associated with poor outcome or even patterns of 
cytokines that may lead to sustained immunosuppression that is experienced by many who 
survive sepsis. Identifying sepsis biomarkers in the sera of septic patients would increase our 
knowledge of the pathophysiological process occurring and would allow for a better targeted 
approach in treating the many morbidities. 
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Thesis Conclusion 
This study characterized the inflammatory mediators from two different inducers of sepsis. The 
first inducer was pandemic H1N1 2009 Influenza A. This represented viral sepsis. The lung 
tissue from these samples demonstrated tissue injury, infiltration of immune cells and apoptotic 
cells in situ. The sera from pandemic H1N1 infected individuals contained high levels of the pro-
inflammatory cytokines TNF-α, IL-1β and IFN-γ. These sera also demonstrated the ability to 
induce apoptosis in cultured fibroblasts which require STAT1 to mediate the apoptotic signal. 
The second inducer of sepsis was from bacteria. Similar to viral samples the bacterial septic sera 
samples had increased levels of TNF-α, IL-1β and IFN-γ. Characterization of these sera 
demonstrated the presence of other inflammatory mediators including chemokines. Different 
profiles of inflammatory mediators are induced by different classes of microbes. Characterization 
of these mediators and their temporal expression will better aid in the understanding of the 
complex nature of sepsis and in the development of better treatment strategies.
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Table A-1. Summary of immunohistochemical staining for H1N1 viral proteins and cytokines in remaining lung tissue. 
Sample no. IHC Score 
for virus 
Location of 
staining 
Cell types with positive staining for virus TNF-α IFN-γ IL-1β 
SJ RI-496-09 + B/I Airway Epithelium and Macrophages + ++ Negative 
SJ RI-497-09 + C/I Macrophages ++ + Negative 
HA AU-09-
000110 
Negative   Negative Negative Negative 
HA AU009-
000073 
+ C/A/I Alveolar Epithelial cells and Macrophages + + Negative 
AF-09-121 + C/I Macrophages + + Negative 
AF-09-174 +++ B/A Type I and II pneumocytes + + Negative 
AF-09-195 + C/I Macrophages + Negative Negative 
AF-09-201 ++++ B/A Type I and II pneumocytes and epithelial cells + + + 
AF-09-206 + B/A/I Alveolar and glandular epithelium and 
macrophage 
+ + Negative 
AF-09-216 + B/A Airway and alveolar epithelial + Negative Negative 
AF-09-234 + C/I Macrophage + + Negative 
Immunohistochemistry staining for viral nucleoprotein and cytokines TNFα, IL-1β and IFN-γ were performed on 5μm sections of lung 
tissue from autopsy samples. Proteins were detected by diaminobenzidine and counterstained with hematoxylin. The level of staining 
is indicated by the symbol + weak staining, ++ strong staining and +++ for heavy staining. Location of staining for viral protein A= 
alveolar, I= interstitial, C= cytoplasmic, N= nuclear and B= both
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Figure A-1. TNF-α stained H1N1 infected lung sections. 5µm sections of formalin fixed paraffin 
embedded lung tissue from autopsy cases of H1N1 infection (A-K) and bacterial sepsis control (L). 
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Figure A-2. IFN-γ stained H1N1 infected lung sections. 5µm sections of formalin fixed paraffin 
embedded lung tissue from autopsy cases of H1N1 infection (A-L) and bacterial sepsis control (M).
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Figure A-3. IL-1β stained H1N1 infected lung sections. 5µm sections of formalin fixed paraffin 
embedded lung tissue from autopsy cases of H1N1 infection (A-K) and bacterial sepsis control (L). 
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Figure A-4 Tunel assay on H1N1 infected lung tissue. Tunel staining was performed on 5 µm formalin 
fixed paraffin embedded H1N1 infected tissue (A-I) and uninfected lung tissue (J). Tunel positive cells stain blue. 
Tissues were counterstained with Nuclear Fast Red. 
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Table A-2. Trypan exclusion assay for uninfected and H1N1 infected sera on cultured 
fibroblasts. 
 
 
 
 
 
 
 
 
 
 
 
 
Trypan blue exclusion assay for 8 uninfected sera (N) and 8 H1N1 infected sera (H). Fibroblast cell lines were 
seeded at 5X10
4
 cells/well in a 96 well plate and were treated with either 5% uninfected sera or 5% H1N1 infected 
sera for 12 hours before the trypan blue assay. Values are averages for percent blue staining cells for each serum. 
         Cell Lines  
Sera HT1080       2fTGH U3A U3AR 
     N1 0.8 0.7 0.6 0.9 
N2 1 1.1 0.8 0.7 
N3 0.6 1.1 0.7 0.9 
N4 1.2 1 1.1 1.3 
N5 0.9 1.2 1 0.7 
N6 1.1 0.8 0.9 1 
N7 1.2 1.4 1.2 0.8 
N8 0.7 1 0.9 0.7 
H1 23.2 22.1 3.5 21.5 
H2 22.1 20.6 2.1 21.3 
H3 18.5 19.4 2.8 18.3 
H4 26.4 24.6 3.2 22.7 
H5 28.4 25.9 1.8 25 
H6 24 26.3 2.6 27.6 
H7 23.9 23.2 3.2 21.8 
H8 20.7 22.5 3.1 23.5 
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Table A-3. TUNEL assay for 8 uninfected and 8 H1N1 infected sera treated cultured fibroblasts. 
        Cell Lines 
Sera HT1080       2fTGH U3A U3AR 
     N1 0.1 0.08 0.07 0.07 
N2 0.12 0.1 0.09 0.09 
N3 0.08 0.1 0.13 0.08 
N4 0.12 0.07 0.09 0.11 
N5 0.09 0.07 0.12 0.06 
N6 0.07 0.13 0.08 0.08 
N7 0.08 0.06 0.11 0.12 
N8 0.11 0.12 0.13 0.13 
H1 0.98 1.05 0.26 1.18 
H2 0.88 0.95 0.28 1.09 
H3 1.1 1.13 0.25 1.08 
H4 0.98 1.09 0.25 0.97 
H5 0.95 0.99 0.21 1.12 
H6 1.12 1.03 0.22 1.19 
H7 1.21 1.25 0.23 1.23 
H8 1.18 1.17 0.19 1.15 
 
TUNEL assay for 8 uninfected sera (N) and 8 H1N1 infected sera (H). Fibroblast cell lines were seeded at 5X10
4
 
cells/well in a 96 well plate and were treated with either 5% uninfected sera or 5% H1N1 infected sera for 12 hours 
before TUNEL assay. Values are averages of duplicate absorbance readings from TUNEL positive cells for each 
serum. 
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Table A-4. Caspase 3 activity assay for 8 uninfected and 8 H1N1 infected sera treated cultured 
fibroblasts  
           Cell Lines  
Sera HT1080       2fTGH U3A U3AR 
     N1 240 200 170 200 
N2 330 230 270 170 
N3 190 180 160 270 
N4 220 190 270 210 
N5 260 170 220 250 
N6 260 310 260 280 
N7 230 210 220 240 
N8 250 230 240 230 
H1 3250 3030 530 3410 
H2 2890 2700 420 3010 
H3 2750 2530 500 2930 
H4 3680 3240 580 3860 
H5 2690 2420 470 2580 
H6 2710 2900 560 2670 
H7 3340 3520 610 3240 
H8 2960 2900 570 3070 
 
Caspase 3 activity assay for 8 uninfected sera (N) and 8 H1N1 infected sera (H). Fibroblast cell lines were seeded at 
5X10
4
 cells/well in a 96 well plate and were treated with either 5% uninfected sera or 5% H1N1 infected sera for 12 
hours before Caspase 3 activity assay. Values are averages of duplicate relative fluorescent unit readings from 
caspase 3 active cells for each serum. 
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Table A-5. Trypan exclusion assay for uninfected and H1N1 infected sera on cultured fibroblasts 
with caspase 3 inhibitor. 
         Cell Lines  
Sera HT1080       2fTGH U3A U3AR 
     N1 0.7 0.9 1.2 0.8 
N2 1.2 1.3 1.7 1.6 
N3 0.9 1 1.3 2.3 
N4 1.5 1.6 2.1 1.6 
N5 1.1 1.2 1.5 1.8 
N6 0.8 1.4 1.3 1 
N7 1.4 1.9 2 2.1 
N8 1.5 1.8 2.2 1.3 
H1 4.8 6.2 0.9 7.4 
H2 5.9 7.3 0.7 6.3 
H3 6.7 5.8 1.2 5 
H4 4 6.1 1.4 6.8 
H5 7.2 6.8 0.8 6.1 
H6 7.5 5.6 1.4 5.7 
H7 6.3 5.4 1.3 6.5 
H8 5.6 4.6 0.8 4.2 
 
Trypan blue exclusion assay for 8 uninfected sera (N) and 8 H1N1 infected sera (H) treated with caspase 3 inhibitor. 
Fibroblast cell lines were seeded at 5X10
4
 cells/well in a 96 well plate and were treated with either 5% uninfected 
sera or 5% H1N1 infected sera and 10 µM caspase 3 inhibitor Ac-DEVD-CHO for 12 hours before the trypan blue 
assay. Values are averages for percent blue staining cells for each serum. 
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